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INTRODUCTION 
“Health is a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity" is the widely accepted definition of health 
given by World Health Organisation
 (1)
. 
Siddha System of Medicine is the first system to emphasize health as the perfect 
state of physical, psychological, social and spiritual component of a human being. It 
accentuates not only a healthy body but also a peaceful mind. Hence, it is unique when 
compared to other medical system. It is the traditional medical system widely practiced 
by the people of Tamil Nadu nowadays. It doesn„t consider treatment and prevention 
separately. The main aim of this system is prevention of disease, alike the proverb - 
Prevention is better than cure.  
It is a multidisciplinary system which comprises knowledge from various subjects 
like chemistry, astrology, cosmology, physics, psychology, spirituality, philosophy, 
botany, etc. 
Siddhars were spiritual adepts who possessed the Ashta Siddis, or the eight 
supernatural powers which could keep the body strong and perfect for External life, 
where there is no Death or Rebirth. According to the Scriptures, there were 18 principle 
Siddhars. Of these 18, Sage Agasthiyar is considered as one of the prominent leader. 
The word 'Siddha" is derived from the word 'Siddhi" which literally means 
attaining perfection of life or heavenly Bliss. The ultimate aim to attain eternal bliss, by 
protecting human body from ageing, degeneration, disease & death and to achieve 
longevity with the admixture of preventive (with attanga yoga), Curative ( with herbs, 
minerals, metals and jeevam medicines), rejuvenation (with kaya kalphas) in the form of 
well- organized system of medicine called siddha system of medicine.  
According to the Siddha medical science, the human body is the replica of the 
universe and built physiologically active by 96 thathuvas. The universe originally 
consisted of atoms which contributed to five basic elements viz earth, water, fire, air and 
ether ( panjaboodhas) which corresponded to the five senses of the human body and they 
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were the fundamental to all things in the world. Hence Siddhar Sattamuni in his text Satta 
Muni Gnanam says, 
'mz;lj;jpYs;sNj gpz;lk;  
gpz;lj;jpYs;sNj mz;lk; 
mz;lKk; gpz;lKk; xd;Nw 
mwpe;Jjhd; ghh;f;Fk;NghNj(2)" 
 The physiological function of the human body is mediated by three humors - 
Vatha, Pitha and Kapha and Seven physical constituents. They are related to Arusuvaigal 
and Panjaboodhas. Under normal conditions, the ratio between these three humors i.e.: 
(Vadham, Pitham, Kabam) 1:1/2:1/4 respectively. The maintenance of their normal order 
ensures the preservation of health and harmonious functioning of the body. When the 
equilibrium of three humors is disturbed, disease is occurred. This is what Saint 
Thiruvalluvar says,  
'kpfpDk; FiwapDk; Neha;nra;Ak; ÁNyhh; 
tsp Kjyh vz;zpa %d;W‟‟(3) 
          kUe;J mjpfhuk; ˗ jpUf;Fws; 
Another salient feature of Siddha medicine is „Food as medicine; medicine as food‟. 
        'czNt kUe;J; kUe;Nj czT" 
  -  gonkhop 
The food which the human body takes and also the drugs used for the disease are 
all made of these five elements (panjaboodhas). Thus as per Siddha every drug is made 
up of panjabhoodas and has got the following properties. They are suvai( taste), gunam     
(character), veeriyam(potency), pirivu(bio-transformation) and magimai(special 
property). These drugs are obtained from the natural sources for medicinal purposes viz., 
Herbal origin, Metals and minerals origin, zoological origin. Diet and life style play a 
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major role not only in health but also in curing disease and various psychological and 
physiological functions of the body.  
In Siddha System of medicine, Eight diagnostic methods ( Naadi, sparisam,na, 
niram, mozhi, vizhi, malam, moothiram) mentioned by Theraiyar, Neerkuri and Neikuri  
are the wonderful diagnostic tools to rule out the diseases, before the signs and symptoms 
appear. 
Siddhars classified diseases in different categories and accounted for total 4448 
diseases in human body. Among them, the diseases of the women pertaining to the 
reproductive organs also explained. Perumbadu Rogam which was explained by the great 
saint Yugi Muni in his text Vaithya Chinthamani is one of the important gynecological 
the problems that clinically correlate with MENORRHAGIA in Modern System of 
Medicine. A healthy woman only can produce a healthy generation. Being a woman, I 
prefer to take PITHA PERUMBADU (Menorrhagia) as my dissertation which is a main 
gynecological problem nowadays and also to give a solution through our Siddha System 
of Medicine. 
Menorrhagia is defined as cyclic bleeding at normal intervals: the bleeding is 
either excessive in amount (> 80ml) or duration (> 7 days) or both. The term Menostaxis 
is often used to denote prolonged bleeding 
(4)
. 
The WHO reports  that  18  million women aged  30-55 years  perceive  their  
menstrual  bleeding  to  be  exorbitant.
(5) 
Totally 30% of worldwide population having 
heavy menstrual blood loss.
(6) 
In developing countries like India, about 20% of DUB 
cases are seen among adolescent and 40% among women above 40 years
(7)
.  
In Modern System of Medicine, as surgical intervention is the only choice, I had 
selected MAAMPISIN CHOORANAM a Poly herbal formulation from Siddha Vaidhiya 
Pathartha Guna Vilakkam- Moola Vargam to give best solution for Perumbadu. So there 
is a need to evaluate the safety and therapeutic efficacy of this classical Siddha 
formulation “Maampisin Chooranam” for scientific validation.     
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AIM AND OBJECTIVES 
AIM:             
  The   aim   of  the  dissertation   study   is  to  analyse  the   selected   disease  
PITHA  PERUMBADU, both  clinically  and   experimentally   with   the   trial  
medicine  MAAMPISIN CHOORANAM. 
OBJECTIVES:  To evaluate the therapeutic efficacy of MAAMPISIN 
CHOORANAM in PITHA PERUMBADU (MENORRHAGIA).  
To collect the various Siddha literatures as well as Modern literatures 
Herbal identification and authentication 
Preparation of Maampisin Chooranam 
Biochemical and physiochemical analysis 
Toxicological and Pharmacological studies 
To  study   the  clinical  course  of  the disease  with  observation  on  the  
etiology, classification, pathology,  differential  diagnosis,  prognosis,  
complications and  treatment  by  Siddha  aspect. 
To  have  an  idea  about  the  incidence of  the disease  with  age,  occupation, 
economical status, habits, family  history and climate conditions.  
To expose the clinical diagnostic methods mentioned by Siddhars to know how 
the disease manifest due to the deranged Mukkutram, Pori pulangal and Ezhu 
Udal thathukkal. 
To have the modern parameters to confirm the diagnosis and prognosis of the 
disease     
To have a clinical trial on the disease Pitha Perumbadu with the Siddha medicine 
MAAMPISIN CHOORANAM 
To subject all patients for thorough investigation before and after treatment 
To find out the statistical analysis and efficacy of the drug through clinical study 
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
ப஧ரும்஧ாடு 
IYAL  (DEFINITION)    
 Perumbadu is defined as the excessive loss of menstrual bleeding which may 
be increased in duration of menstrual bleeding or heavier blood flow without any 
change in the cycle length 
(8)
. 
 
NOI VARUM VAZHI (AETIOLOGY) 
Yugi vaidhiya Chinthamani, 
“கருதியன க஦நா஦ பகாடுமந பெய்து 
கணயம஦யன ஥ிந்தம஦தான் பொன்஦ ய஧ரும் 
஧ருதினின்னென் ந஬ெ஬த்மத யிட்ட ய஧ரும் 
஧பயதெியன மமகம஭ப் ஧மிக்கின்ய஫ார்க்கும் 
குருதியன னிமபக்கின்஫ கா஬ந் தன்஦ில் 
கூொநல் ன௄ருரெங்மக ஧ண்ணிய஦ார்க்கும் 
கருதியன ஧பயனாகம் யிரும்஧ி ய஦ார்க்கும் 
சுருக்கிய஬ ப஧ரும்஧ா டுற்஧யிக்குந் தாயந 
 
தாப஦ன்஫ காபணிகள் நிகுக்மக னாலும் 
ெண்டா஭க் யகா஧த்தின் ெர௅ப்஧ி஦ாலும் 
ஊப஦ன்஫ நாநிெங்கள் ப஧ாெித்த ஬ாலும் 
உ஫க்கநின்஫ி யிமித்த஬ா லூமித் தீனால் 
஧ாப஦ன்஫ ஧ெினின்஫ிப் ப஧ாெிக்மக னாலும் 
஧ாபநாஞ் சுமநயாங்கல் ஧கலு஫க்கம் 
கூப஦ன்஫ குர௃க்க஬ாம் னெடக்கித் தூங்கல் 
குரூபநாம் ப஧ரும்஧ாடு பகாட்டுந்தாய஦.(9) 
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 Women those who abuse or show severe cruel activity to her 
husband. 
 Women who void urine and faeces in front of sun 
 Women who criticize sages and poor people 
 Women who have sexual intercourse at the time of menstruation 
 Women who indulge in excessive sexual intercourse 
 Women with vigorous anger 
 Women often taking non-vegetarian foods. 
 Sleeplessness without rest 
 Taking food without appetite 
 Lifting heavy loads 
 Daytime sleep 
  Sleeping in flexed position. 
 
These conditions will cause the disease, Perumbadu Rogam. 
Mega noi, Soothaga Nool and Arivaiyar Chinthamani, 
 
“கண்டாயனா ப஧ரும்஧ாடு க஬ந்த நார்க்கம் 
கருதிக் யகள் நின்஦ாய஭ ஥ன்஫ாய் இன்னும் 
பகாண்ட ஧டிகாபனெள்஭ யமககள் தின்஫ால் 
கூ஫ாக நாதயிமட கா஬ம் தன்஦ில் 
யிண்டாலும் யாய்வு அது நிஞ்ெி஦ாலும் 
யி஭ங்கும் நாநிெம் அதிகம் ன௄ெித்ததாலும் 
உண்டாலும் நந்தநதில் ன௄ெித்ததாலும் 
உ஫க்கநது ஒமிந்த யிதத்தாலும். 
 
ஆகுயந கடும் சுநபடடுப்஧தாலும் 
கதிப்஧ாக ஧கலு஫க்கம் ஧கல் ெம்ய஧ாகம் 
஧ாகு ப஧஫ குர௃க்கதுதான் கூ஦ிக் பகாண்டு 
஧ண்஧ாகயய உ஫ங்கும் தன்மநனாலும் 
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யாகு ப஧஫யய அதிக ன௄ணர்ச்ெினாலும் 
யலுயாக யநகநது உற்஧யித்து 
             தாகனெ஫ சூபடழும்஧ி த஭யாய் ஥ீ஫ி 
த஦ி யனர௃ம் கருக்குமியும் ன௄ண்ணுண்டாயந.”(10) 
 
 
 Excessive intake of spicy foods 
 Increase of Vatha during menstrual period 
 Increased intake of non-vegetarian foods 
 Intake of food during indigestion 
 Insomnia 
 Lifting heavy weights 
 Daytime sleep 
 Sexual act during daytime 
 Sleeping in flexed and Improper posture 
 Increased sexual intellectual. 
 
 
Agathiyar Gunavagadam, 
               “ ஧ாயப஥ீ ப஧ரும்஧ாடு யரும் யமகமனக் யக஭ாய் 
                     ஧க்குயநாய் யருகின்஫ கண்டநாம஬ 
                   ஊயப஥ீ னேத்திப குண்டிக்கானின் யபாகம் 
                     உத்தநய஦ ன௃ர௅கா யபாகந் தானும் 
                    யதயப஥ீ ஥ாட்஧ட்ட ஧ாண்டு யபாகம் 
பத஭ியாக இபத்தயபாகம் தன்஦ா ம஬னா 
                   ெீயப஥ீ ெிம஦ப்ம஧க்கும் கருப்ம஧க்கு நப்஧ா 
                     ெி஫ப்஧ாக அதிகபத்த யநர௃ங்காய஦. 
 
                  காணுயாய் சூதகம் பய஭ினாகுநப்஧ா 
            கருப்ம஧தான் அமம஬பகாண்டு ய஧ாய தாய஬ 
                  ன௅ணுயாய் ெம்ய஧ாக நதிகத்தா லும் 
                     ப஧ால்஬ாத ன௄த்துக஭ாற் கட்டினா லும் 
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              ய஧ணுயாய் ப஧ரும்஧ா டுண்டா பநன்ர௃ 
          ப஧஬நாக தீதான் பொல்லுயாய் உ஬கத்யதார்க்கு 
                காணுயாய் அப்ய஧ாது கருப்ம஧ ஥ின்ர௃ 
                           கருயா஦ பத்தத்தான் யருகுந்தாய஦.”(11) 
                                                            
According to the text Agathiyar Gunavagadam, Perumbadu occurs in association with 
the following diseases:                                          
 Tubercular adenitis 
 Renal Diseases 
 Chronic Aneamia 
 Pelvic Inflammatory Diseases 
 Uterine congestion 
 Excessive coitus 
 Benign and Malignant Tumours 
T.V. Sambasivam pillai,  
 Perumbadu is an immoderate secretion of the menstrual 
discharge. 
 Uterine blood vessels lose their strength, muscle fibers get 
congested leading to Menorrhagia.
(12)
 
 
Anubhoga Vaidhya Deva Ragasiyam- Shthiriroga Nithanamum, Sigichchaiyum  
  Intake of food which increases body heat.   
  Excessive intake of food.   
  Indigestion.   
  Uterine congestion.   
  Excessive coitus   
  Climbing hills.   
  Excess walking and excess sleep.   
  Fasting.   
  Loss of body weight.  
  Lifting heavy weights  
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  Injury by sticks and rods  
  Sleeping during Daytime(13). 
 
SOOTHAGAM UNDAGUM VITHAM  
In Mega Noi, Soothaga Nool mattrum Arivaiyar Chinthamani, the process of 
Menstrual Cycle is mentioned. 
  “திங்கல௃ர௃ நங்மகனர்கள் பகற்஧ாெனநமத 
                                            தாங்கினிரு ெியிமகயுண்டு 
ெியிமகனிரு ஧க்கனெம் வீெியன 
  ஥ிற்குநதி஦ின்ப஫ாரு குமல் ஥பம்ன௄ 
஧ங்கந஫யயபனழும் அடியனிர௃ யனா஦ியும் 
சுற்஫ிப் ஧ிமணந்து பகாண்டு 
஧கருநதிப஬ாரு னெம஦ இபத்தாெனநமதக் 
கவ்யிக் குயிந்திருக்கும் 
 
இங்கிதநதாகயய நர௃னெம஦னது 
அாிமயனர் பகற்஧ாெனம் ன௄குந்து 
இ஦ிதானபயினுட யான஭யாகயய 
னேயிப஬மெந்து ஥ிற்கும் 
நங்க஭நதானிந்த ஥ாதக்குமல் 
யமி பத்தாெனத்தி஦ின்ர௃ 
நர௃யக஬யய காாிபத்தம் சுபந்தி஦ி 
பகற்஧ாெனததிய஬ தான் 
 
஥ிதனெநிது தய஫ாது ஒயப து஭ியிழும் 
ஆ஫ஞ்ெதாம் ஥ா஭ிய஬ 
ய஥ெபநாரு குமல்யமி உருகினது பய஭ினிய஬ 
஧ாயுநது யனா஦ி யமினாய் 
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஧தநாகயய சுகயதகினதுயாகிப஬ா 
ன௅த்த னெதல் னேன்ர௃ ஥ால௃ம் 
஧கருதி஦ி யநாபாற் கமஞ்சு ஥ிம஫ ஧ாயுயந 
யநகநதி஦ால் சூட்டி஦ால் 
இதநா஦ யாயுயால் கிருநினின் ஌துயால் 
ன௅த்த ஧ின் கணயய஦ாயட 
யெருயதி஦ாய஬யும் கடு஥மடக஭ார௅஦ி 
சுநடு பயனில் தாக்குயதி஦ால் 
 
 
யிதநா஦ ஥ாதநது கூடும் கும஫ந்திடும் 
பகற்஧நில்஬ாந஬ாகும் 
யிள்ல௃யநாபார௃ யமக யாயுயது 
துதித்திடும் யகல௃ ஥ீ ஒவ்பயான்஫ாய்(14). 
                                                                                 
PERUMBADU – CLINICAL FEATURES     
                        
Mega noi, Soothaga Nool mattrum Arivaiyar Chinthamani, 
                                                                                
“மகயுடன் காலுங் காந்துங் காத்திப னெ஬ர்ந்து யற்ர௃ 
மநன஬ாங் க஬யி தன்ம஦ நர௃த்திடுங் கர்ப்஧ங் யகடாஞ் 
பெய்ன஥ீர் ய஧ாலுஞ் ெற்ய஫ ெியந்திடும் குருதிய஧ாலும் 
ப஧ய்யுயந னாகில் நாய஦! ப஧ரும்஧ாபடன்஫஫ிகுவீயப’’(15) 
 
 Burning sensation of upper and lower limbs 
 Emaciation of Body 
 Loss of libido 
 Failure to conceive 
 Watery or reddish discharge 
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Aaviyalikum Amuthamurai Churukkam,                            
“஧ார்த்திடயய நங்மகனர்க் கிபத்த சூம஬ 
஧கருகிய஫ ஦டியனிற்஫ில் ஧ற்஫ி ஥ிற்கும் 
 யகார்த்திடயய உதிபநது திபண்டு யநதான் 
      பகாதிப்ப஧டுத்து நாதயிடாய்க் கா஬ந் தன்஦ில் 
 யெர்த்திடயய சூதகனெம் நிகுந்து காணும் 
             ெிர௃யமினாய்க் கருயமியும் ன௄஫ண்டு ம஭க்கும் 
         ஌ர்த்துடய஦ பதாமடனிடுப்ன௄ உம஭ச்ெ ஬ாகும் 
                       இபத்தசூம஬க் குணநிதுயய ஧ாரு ஧ாயப.(16)” 
 
 Excessive menstrual bleeding  
 Mild abdominal pain 
 Pain in thighs and hip region. 
 
Agathiyar Gunavagadam,   
                                                                  
“இபத்த பநாருக்கால் தமகனாநல் ப஬஦யய யனாடுய஧ால்  
 வீழுந்திருக்கும் ெிபத்தில் க஦ப்ன௄னெண்டாகும் திதநாய் ெிதகிய஫ யிமபத்தம் 
ொத்த பத்த யபாகபந஦ச் பொல்லும் ஥ல்஬ யல்஬யப.(17)” 
                                                                                      
         
 Excessive bleeding with clots 
 Head ache 
 Scattered blood. 
  
 
Mega noi, Soothaga Nool mattrum Arivaiyar Chinthamani   
                                   
“பய஭ியாக இபத்த சூம஬ பொல்஬க் யகல௃ 
யிமபயாக அடியனிற்஫ில் இபத்தம் 
பத஭ியாக ன௅க்குநந்த கா஬ம் தன்஦ில் 
திட்டநாய் இபத்தநது அதிகம் ஧ாயும் 
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க஭ியாக யன஫த஦ில் ய஥ாவுண்டாகும் 
கருயமிக்கும் யனர௃஧ிபட்டும் க஦ ய஥ாயாகும் 
அ஭ியாக இடுப்ன௄ துமட அனர்ந்து ய஧ாகும் 
அ஫ிகுயாய் இபத்த சூம஬பனன்ர௃ பெப்ய஧.(18)”  
                                                                                                                                                                                                                                                                                                                                                                                                          
 Excessive menstruation 
 Lower abdominal pain 
 Pain in thighs and hip region. 
 
NOI   ENN (CLASSIFICATION) 
In Yugi vaithiya chinthamani-800, about 4 types of Perumbadu diseases are 
described. 
“உமப பெய்த ப஧ரும்஧ாடு ஥ா஬ தாகும் 
உகந்துயந யாதத்தின் ெிபாய பநான்ர௃ 
ன௄மப பெய்த ஧ித்தத்தின் ெிபாய பநான்ர௃ 
ய஧பா஦ யெட்டுநத்தின் ெிபாய பநான்ர௃ 
துமப பெய்த பதாந்தநாஞ் ெிபாய பநான்ர௃ 
துமகபனல்஬ாம் ஥ாயிதச் ெிபாய நாச்சு 
கமபபெய்த யிதனுமடன உற்஧த்தி பனல்஬ாம் 
கண்ட஧டி பொல்஬யய கருதிடாயன’’ (19) 
 
 
 VATHA PERUMBADU 
 PITHA PERUMBADU 
 KABHA PERUMBADU 
 THRITHOSA PERUMBADU. 
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PITHA PERUMBADU 
 
“ஆபநன்஫ யன்஦த்மத இ஫ங்பகாட் டாது 
அழுகின்஫ நஞ்ெள் ஥ி஫ம் ய஧ா஬ ஊற்ர௃ம் 
யயபநன்஫ யனா஦ினிய஬ யயக்கா டுண்டாம் 
யந஦ியுயநா பயல௃த்துயந பத்தம் ய஧ாகும் 
காபநன்஫ கால்மகயு நமற்஫ ஬ாகும் 
  கருக஬ாய்க் கட்டிய஧ா லுதிபம் வீழும் 
                                யதபநன்஫ ெிர௃கடுப்஧ா நங்க பநல்஬ாம் 
ெீாின யதார் ஧ித்தத்தின் ெிபாய நாயந. (20)” 
                         
 Loss of  appetite 
 Menstrual bleeding with slight yellowing color tinch 
 Soreness of vagina 
 Pale color of the body 
 General weakness of  limbs 
 Menstrual bleeding with black coloured blood clots 
 Body Pain 
 
 
Mega noi, Soothaga Nool mattrum Arivaiyar Chinthamani, 
                                                                                                                                                                                                                                                                   
 
PITHA PERUMBADU 
 
“பொல்லுயயன் ஧ித்தத்தின் ப஧ரும்஧ாபடன்஫ால் 
சுடும் நஞ்ெள் ஥ி஫ம் பபத்தம் பயர௃க்கும் அன்஦ம் 
ெல்ர௅னநாய் யனா஦ினது பயந்து ஥ீர௃ம் 
ொயாக உடல் பயல௃க்கும் பத்தம் யற்ர௃ம் 
பநல்஬யய கால் மகயும் காந்தலுண்டாம் 
பநய்யுருகி கட்டினதாய் இபத்தம் ய஧ாகும் 
இல்ம஬னி஦ி யதகநது உம஭யும் ெற்ர௃ 
இது ஧ித்த ப஧ரும்஧ாபடன்ர௃ உமபக்க஬ாயந(21)” 
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 Pale coloured menstrual bleeding with yellowish tinch. 
 Aversion of  food 
 Burning sensation on vagina 
 Pale color of the skin due to decreased hemoglobin 
 Burning sensation on palms and soles 
 Menstrual bleeding with clots 
 Pain all over the body. 
 
CLASSIFICATION OF OTHER PERUMBADU TYPES 
 
Yugi Vaithiya Chinthamani,   
 
VATHA PERUMBADU 
 
               “கூடுயந தம஬யர௅யு யநற்க டுப்ன௄ம் 
                     கூ஫ா஦ னெதுகிடுப்ன௄க். குமடச்ெ லுண்டாம் 
               யாடுயந யதகபந஬ாங் கருக்க ஬ாகும் 
                     நாதயிடாய் காித்துயந மநந்தன் ய஧ா஬ாம் 
               ஊடுயந யனிர௄தி உம஭ச்ெ ஬ாகி 
                     ஊற்ர௃யந பெந் ஥ி஫னெங் கருக ஬ாகத் 
               யதடுயந துற்கந்தஞ் யெப பயாட்டா  
                     பெகந஫ின யாதத்தின் ெிபாய நாயந(22)” 
 Head ache 
 Pain in lumbar and hip region 
 Abdominal distension 
 Body pain 
 Dark coloured menstrual bleeding 
 Menstrual bleeding with foul smell. 
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KABHA PERUMBADU 
                                “ஆகுயந பயள்ம஭ ஥ி஫நாக ஊற்ர௃ம் 
                    அர௅னா஦ ஥ாற்஫ந்தான்  நிகவுண் டாகும் 
                யயகுயந வுடம்ப஧ங்கும் யின௅தி ன௅க்கும் 
                     பயந்தம஬ா யுடம்ப஧ங்கும் ஋ாிச்ெ ஬ாகும் 
              ஧ாகுயந ஧ட஧டப்ன௄ னேச்சு னெண்டாகும் 
                     ஧ாபநாங் யகாமமபனாடு நனக்க நாகும்           
                யதகுயந னடிக்கடிக்கு நனக்க நாகும் 
                     யெட்டுநத்தின் ெிபாய பநன்ய஫ பெப்஧ாயந(23)” 
 
 Pale coloured menstrual bleeding 
 Menstrual bleeding with Foul smell 
 Salty appearance on the body 
 Burning sensation on all over the body  
 Palpitation 
 Cough with fatigue 
 
THRITHOSHA PERUMBADU 
 
              “பெப்஧யய கருஙல்஬ாய்ச் ெியப்ன௄ நாகும் 
                     யெர்ந்ததிய஬ கட்டினாய்க் கருப்஧ாய் வீழும் 
                உப்஧யய யனி஫து னெல்ம஬ச்ெ ஬ாகும் 
                    ஊெ஬ா ஥ாற்஫னெட ப஦ாழுக்க நாகும் 
                ஥ம்஧யய நஞ்ெள் ஥ி஫ ஥னப்ன௄ நாகும் 
                             ஥ாணியன தம஬தானு ஥டுக்க ஬ாகும் 
                துப்஧யய யாய் ஥ீரு நிகயய வூற்ர௃ம் 
                        பதாந்தநாம் ப஧ரும்஧ாடு சூட்டிய஦ாயந(24)” 
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 Dark brown colored menstrual bleeding with clots 
 Abdominal distension with pain 
 Menstrual bleeding with foul smell 
 Tremors of the  head 
 Increased salivation. 
 
Mega noi, Soothaga Nool and Arivaiyar Chinthamani,                                                                                                                                                                                                                                                                                                                      
VATHA PERUMBADU 
                “஧ாடாநல் யாதத்தின் ப஧ரும்஧ாடுற்஫ால் 
                     ஧ண்஧ாக தம஬யர௅க்கும் யதகம் ய஥ாகும் 
                ஥ாடாநல் னெதுபகாடு இடுப்ன௄ தானும் 
                     ப஥ாந்து நிக யருத்தநிகும் உம஭வுண்டாகும் 
                கூடாகவுடல் பநர௅யும் கருகும் யதகம் 
                     பகாள்ல௃ம் நாதயிடாய் கா஬ம் யனர௃ ய஥ாகும் 
                ஊடாகயய உருல௃ம் குமந்மத ய஧ாய஬ 
                     உர௃ ப஧ருநல் பெந்஥ி஫நாய் இபத்தம் ஥ார௃ம்(25)” 
 
 Head ache 
  Pain in all over the body 
 Pain in lumbar and hip region 
 Loss of  weight 
 Lower abdomen pain during menstruation 
 Dark red colored menstrual bleeding with foul smell. 
 
KABHA PERUMBADU  
                 “ய஧ாயந யெர்ப்஧஦த்தின் ப஧ரும்஧ாபடன்஫ால் 
                     ப஧ாருந்து பயள்ம஭ ஥ி஫நாக பத்தம் யிழும் 
                யாகுப஧஫யய ஥ார௃ம் யதகம் தானும் 
                     ய஭ர் ஥ீர௃ம் ய஧ாப஬ாியும் அமலும் யதகம் 
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                தாகனெர௃ம் ஧ட஧டத்து னேச்சு யாங்கும் 
                     த஦ித்த க஧நிருநப஬ாடு யயவுண்டாகும் 
                ஧ாகுப஧஫ அடிக்கடி நனக்கனெண்டாகும் 
                     ஧கருயயன் யெர்ப்஧஦த்தின் ப஧ரும் ஧ாபடன்ய஫(26)” 
 
 Pale colored menstrual bleeding 
 Menstruation with foul smell 
 Burning sensation on whole body 
 Increased thirst 
 Palpitation 
 Dyspnea 
 Cough 
 Fatigue. 
 
THRITHOSHA PERUMBADU 
 
                “உண்டா஦ திாியதார ப஧ரும்஧ாபடன்஫ால் 
                     உள்஭஧டி கல்லுப் ய஧ால் கட்டினாகும்  
                யிண்டு கர௃ப்ப்஧ாய் ெிகப்஧ாய் நஞ்ெள் ய஧ாலும் 
                     யிதம் யிதநாய் இபத்தநது ஥ி஫ம் நா஫ிப் ய஧ாம் 
               கண்டாலும் யனர௃ம஭யும் ஥ாற்஫ம் நீர௃ம் 
                     கடிதா஦ தம஬ ஥டுக்கம் யாய் ஥ீரூர௃ம் 
                நிண்டாத திாியதார ப஧ரும்஧ாடின் 
                     நிகு ப஧ருமநயுள்஭஧டி பெப்஧ிய஦ய஦(27)” 
 
 Black, red or yellow coloured menstrual bleeding 
 Abdominal Distension 
 Foul smell Menstrual bleeding 
 Tremors of the head 
 Increased salivation. 
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SAATHIYAM AND ASAATHIYAM (CURABLE AND INCURABLE) 
 
Yugi Vaithiya Chinthamani,
 
 
      “சூடினயதா பொத்தினத்மதச் பொல்஬க் யக஭ாய் 
பொல்லும்யெட்஧ ப஧ரும்஧ாடு பதாந்தெெி பாயம் 
ன௅ட்டி஦யதா ாிபண்டும் ஧ிமமக் பகாட் டாது 
   ன௄கமா஦ ொத்தினத்மத யி஭ம்஧க் யக஭ாய் 
யாட்டி஦யதார் யாதத்தின் ப஧ரும்஧ா யடாடு 
   யமகனா஦ ஧ித்தத்தின் ெிபாயந்த் தானும் 
தீட்டி஦யதார் நருந்துக்குச் பெனனெ நாகும் 
பெப்஧ி஦யதார் ஥ன்னூம஬த் பத஭ிந்து ஧ாயப(28)” 
 
 Vatha perumbadu and pitha perumbadu are curable. 
 Kabha perumbadu and thrithosha perumbadu are incurable. 
 
 
Mega noi, Soothaga Nool and Arivaiyar Chinthamani 
                                                                                                                                                                                                                                                                                                                    
“ொற்ர௃யயன் யாதத்தின் ப஧ரும்஧ாபடான்ர௃ 
  ெர௅னாநல் ஧ித்த ப஧ரும்஧ாடு தானும் 
ய஧ாற்஫ினயதார் யெர்ப்஧ ப஧ரும்஧ாபடான்ர௃ 
ப஧ாருந்து திாியதார ப஧ரும்஧ாடு ஥ா஬ாம் 
ஆற்஫ினயதார் யாத ப஧ரும் ஧ாடிய஦ாடு 
           அதிகநாய் ஧ித்த ப஧ரும்஧ாடு தீரும் 
நாற்஫ினயதார் யெர்ப்஧ ப஧ரும் ஧ாடிய஦ாடு 
                         நருவு திாியதார ப஧ரும்஧ாடு அொத்தினம்(29)” 
 
                                                                                                                                                                   
 Vatha perumbadu and pitha perumbadu are curable. 
 Kabha perumbadu and thrithosha perumbadu are incurable.  
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THOADA KURIKUNANGAL (SEQUELAE OF COMPLICATIONS)       
 
                
            “யதகத்தூர௃ ந஦லும் தீதாநதி ப஬ாிச்ெல் 
              யயகப்ப஧ரும்஧ாடு பயண்ணி஫நாய்ப்—ய஧ாகயதில் 
             ஥ாற்஫யநல் னேச்சு ஥யி஬க்க஧ நனக்கம் 
              யதாற்஫வுடல் ொயுஞ் பொல்(30)” 
         
                                                                 
 Burning sensation on all over the body 
 White coloured menstrual bleeding 
 Menstrual bleeding with Foul smell 
 Dyspnea 
 Giddiness 
 
MUKKUTTRA VERUPAADUGAL (PATHOLOGY) 
 According to Siddha System, Body is constituted by 96 thathuvas. Normal 
structural and physiological state of the body is maintained by equilibrium with 
Mukkuttram and seven Udarkattukal. 
As the Udarkattukal are affected by the extrinsic and intrinsic factors, there is 
deterioration in the structural and functional status of the body. When the causative 
factor affects Udarkattukal and Mukkuttram, it results in incoordination of functions. 
Thereby the diseases manifest and expose its clinical features. 
 In Perumbadu, clinical condition is due to the imbalance of Pitham. Pitham is 
deranged primarily and later it deranges Vatha and the derangement of Pitha- Vatha 
leads to the derangement of Abaanan which in turn cause the disease. The 
pathogenesis of the disease depends upon the affected Pitha and Vatha.  
DIAGNOSIS OF PERUMBADU BASED ON SIDDHA SYSTEM: 
                             According to Siddha System, the diagnosis of a disease is reached by 
the Envagai thervu, Uyirthathukkal and Udal thathukkal. 
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ENVAGAI THERVU OR PINIARIMURAIMAI 
The disease Perumbadu Rogam was diagnosed by the following methods: 
 Poriyaal arithal  
 Pulanaal arithal  
 Vinaathal  
 Uyir thathukkal 
 Udal thathukkal  
 Envagai thervu 
PORIAL ARITHAL – understanding by the fire organs of perception 
 Nose 
 Tongue 
 Eye 
 Skin 
 Ear 
  PULANAAL ARITHAL – understanding by the sense objects 
 Odour (smell) 
 Taste 
 Vision 
 Touch (tactile) 
 Sound (hearing) 
 
VINAATHAL (Interrogation) 
                        Patient name, age, occupation, address, socio-economic status, family 
history, diet habits prone for any allergens, period of suffering, history of previous 
episode,  history of treatment, habits etc are  noted  through  interrogation. 
 
UYIRTHATHUKAL 
                         Panchaboothams are manifested in the body as three vital forces. 
 Vaatham 
 Pittham 
 Kabham 
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VAATHAM : 
It is the combination of vaayu and aakasa boothams. It is responsible for all 
the movements of the body. It helps in the uniform functioning of seven Udal 
thathukkal 
 
 
The sites of vaatham: 
 Umblicus, rectum, faecal matters, abdomen, anus, bones, hip joint, naval, 
plexus, joints, hair follicles and muscles.  
 
Vaatham has ten types: 
1. Praanan (uyirkaal) :  
This controls knowledge, mind and five sense organs, which are useful for 
breathing and digestion. 
2. Abaanan (Keezh nokku kaal) :  
This is responsible for all downward movements such as passing urine, stools, 
semen, menstrual flow etc. 
3. Samaanan (Nadukkaal) :  
This aids in proper digestion. 
4. Viyaanan (paravukaal).   
This is responsible for all movements of all parts of the body. 
5. Uthaanan (Mel Nokkukaal)  
Responsible of all upward visceral movements, such as vomiting, eructation and 
nausea. 
6. Naagan : 
Responsible for opening and closing the eyes. 
7. Koorman :  
Responsible for vision and yawning. 
8. Kirukaran : 
Responsible for salivation, nasal secretion and appetite. 
9. Devathatthan :  
Resposible for Laziness, sleeping and anger. 
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10.Thananjeyan :  
Produces bloating of the body after death.  It escapes on the third day after death 
bursting out of the cranium. 
 In perumbadu Rogam 
Praanan - Affected (Dyspnoea, breathlessness) 
Abaanan          - Affected (Excessive, prolonged 
Menstruation) 
Samaanan - Affected (loss of appetite)                      
Viyaanan - Affected (body pain) 
Uthaanan - Affected (Nausea, vomiting) 
Naagan - Normal 
Koorman  - Normal 
Kirukaran - Normal 
Devathatthan - Affected (Tiredness) 
 
PITHAM :  
It is the manifestation of „THEE‟ bootham in the body.  It is the metabolic 
thermal life force of the body.  It carries out digestion, absorption, metabolism, 
colouring of blood etc. 
 
 The sites of Pittham: 
 Praana vaayu, urinary bladder, moolaakkini, heart, umblical region, abdomen, 
stomach, sweat, saliva, blood, eyes and skin. 
 
Pitham has 5 types  
 
            1. Analagam    : It promotes appetite and helps in digestion. 
2. Ranjagam    : It gives colour to the blood. 
3. Praasagam   : It gives complexion to the skin. 
            4. Aalosagam   : It brightens the eyes. 
5. Saathagam   : It controls the whole body.  It has the property to fulfil 
                           all the activities which the mind desires. 
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In Perumbadu Rogam          
 Anal pittham            -      Affected (Loss of appetite) 
 Ranjaga Pittham      -       Affected (low Hb level) 
 Saathaga Pittham     -      Affected (General malaise) 
 Aalosaga Pittham     -      Normal 
 Praasaga  Pittham    -      Affected(Pallor of skin) 
 
KABHAM : 
         It has Neer and Mann boothams.  It is responsible for co-ordination and 
defence mechanisms of the body. 
 
The sites of Kabham : 
                    Samaana vaayu, semen, suzhumunai, blood, phlegm, bone marrow, nose, 
chest, nerve, bone, brain, eyes and joints. 
 
Kabham has 5 types 
         1. Avalambagam : Lies in the lungs, controls the heart and other kabhams. 
2. Kilethagam      : Lies in the stomach, makes the food moist, soft and helps 
in    digestion. 
         3. Pothagam         : Responsible for identifying taste. 
4. Tharpagam      : Present in the head and responsible for the coolness of 
both eyes. 
5. Santhigam      : Responsible for lubrication and free movements of joints.  
It is situated in the joints. 
In Perumbadu Rogam 
 Avalambagam           - - Normal 
 Kilethagam                - - Affected (loss of appetite) 
 Pothagam                   - - Normal 
 Tharpagam                - - Normal 
 Santhigam                 - - Affected(Low back pain) 
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EZHU UDAL THATHUKKAL  
 
Normal functions : 
Saaram   
 It gives the good spirit to body and mind. 
Senneer 
 Blood imparts colour to the body and nourishes the muscle responsible for the  
            ability, intellect of the individual. 
Oon  
 It gives shape to the body according to the requirements for the physical 
activity,  
            nourishes bone. 
Kozhuppu  
 It helps in lubrication of different organs. 
Enbu  
 Supports and responsible for posture and  movements of  the body. 
Moolai  
 It fills the bony cavity and gives nourishment. 
Suronitham  
 It is responsible for the reproduction. 
In Perumbadu Rogam  
Saaram -  Affected (Tiredness) 
Senneer -  Affected (pallor) 
Oon  -  Normal  
Kozhuppu -  Normal 
Enbu  -  Affected (low back pain) 
Moolai  -  Normal 
Suronitham - Affected (Excessive or prolonged menstruation) 
                                                                                                                                     
ENVAGAI THERVU 
                      “பநய்க்கு஫ி ஥ி஫ந்பதா஦ி யிமி஥ாயிருந஬ம் மகக்கு஫ி’’(31) 
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Envagai thervugal can be done by the following, 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Malam 
 Moothiram 
 Naadi 
 Sparisam 
 
 NAA (Tongue) 
 Colour 
 Coating 
 Taste 
 Dryness 
 Ulceration  
            In Perumbadu Rogam, tongue is not affected but non-specific and unrelated 
symptoms such as dryness and coating may be seen in some cases. 
 
NIRAM (Colour) 
 Colour of the Skin 
 In Perumbadu Rogam, Paleness of skin may be seen due to excessive 
menstruation. 
 
MOZHI (Voice) 
 Articulation or speech 
 In Perumbadu Rogam, low pitched voice may be noted due to severe pain in 
lower abdomen. 
 
VIZHI (Eyes)  
 Niram  (Pallor, icterus) 
 In Perumbadu Rogam, pallor may be noted. 
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MALAM (Motion) 
 Niram – Colour 
 Irugal, Ilagal- consistency 
 Manam – Odour 
 In Perumbadu Rogam, constipation may be seen. 
 
MOOTHIRAM (Urine) 
Rules for the Collection of Sample urine:                      
 “அருந்துநா஫ிபதனெம் அயியபாதநதாய் 
        அஃகல் அ஬ர்தல் அகா஬வூன் தயிர்ந்தமற் 
     குற்஫஭யருந்தி உ஫ங்கி மயகம஫ 
     ஆடிக்க஬ெத் தாயியன காது ப஧ய் 
     பதாருனெகூர்த்தக் கம஬க்குட்஧டு ஥ீாின் 
            ஥ி஫க்கு஫ி ப஥ய்க்கு஫ி ஥ிருநித்தல் கடய஦(32)” 
The patient must take well cooked food in the previous day. The intake must 
be proportionate to the degree of his appetite. Food intake should be taken, at 
appropriate time. The patient must have sound sleep on the previous night. The urine 
is collected on the dawn of the next day in a glass container and closed immediately to 
prevent contamination. This specimen must be examined with in one and half hours. 
This procedure should be followed strictly to get accurate observation of Neerkuri and 
Neikuri. 
 
NEERKURI 
The collected urine should be noted for the following 5 characters, 
 Niram            -           Colour 
 Edai  - Specific gravity 
 Nurai  - Frothy 
 Manam             - Odour 
 Enjal  - Deposit 
 
                In Perumbadu, the urine is clear without froth. 
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NEIKURI 
                                “ ஥ி஫க்கு஫ிக் குமபத்த ஥ிருநாண ஥ீாிற் 
                                  ெி஫க்க பயண்பணய்யனார் ெிர௃து஭ி ஥டுயிடுத் 
                                  பதன்ர௃஫த் தி஫ந்பதார௅ ஌காதமநத்ததி 
                                  ஥ின்஫தியம஬ ய஧ாம் ப஥஫ியிமின஫ிவும் 
                                  பென்஫து ன௄கலுஞ் பெய்திமன யுணயப(33)”          
  This stanza describes the speciality of Neikuri. Of all diagnostic methods, 
Neikuri reveals the true nature of the disease and prevents wrong diagnosis. 
                               Snake like appearance-Vatham 
                               Ring like appearance-Pitham 
                               Pearl like appearance-Kabham 
NAADI (PULSE) 
                ஥ாடி னேன்ம஫யும் ஥ாடிடுங் காம஬ 
                 ஥டுயிபல் ஥ாடிமன ஥ாடியன கணிப்஧ான் 
                ஥ற்஫யர்க்குருபய஦ ஥யிலு நம஫யன(34).    
                                                           
  Naadi is a Unique Siddha Pulse reading method and it should be felt and not 
read. Different gaits of Vazhi , Azhal, Iyam  like branching, jumping, mixing, rotating 
and compression can be identified.  
 
NAADI INDICATING PERUMBADU ROGAM 
In Perumbadu  Rogam, Pitha naadi and vathathil ushna naadi was diagnosed 
 
                 “உர௃தியுள்஭ ஧ித்தநது யதான்஫ில் பயப்ன௄  
                     உஷ்ணயாயு யத்திசுப நதிொ பங்கள் 
ந஫தியுடன் கிர௃கிர௃ப்ன௄ ஧னித்தின யபாகம் 
                     ய஭ர்யொமக னமப஬ாிவு காந்தல் மகப்ன௄ 
                இருதனத்தில் க஬க்கநது ந஫ப்ன௄ தாகம் 
                     ஋ழுங்க஦வு யநனம஦வு நனக்க னேர்ச்மெ 
                ெி஫ிதுப஧ரும் ஧ாடுபத்தம் ஧ிபயந கங்கள் 
                     யெர்ந்துநிகு ஧ிணி஧஬வுஞ் ெி஫க்குந் தாய஦(35) 
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                “ெி஫ப்஧ா஦ யாதத்தி லுட்டிணந் தாய஦  
                     யெர்ந்திடுகி ஬திொப னெம஭ச்ெல் யாயு 
                உமபப்஧ா஦ ப஧ாருநப஬ாடு அக்கி஦ி நந்தம் 
                     உள்஭ாகும் ஥ீர்ச்ெிர௃ப்ன௄ ஧ிபயந கங்கள் 
                ஧ி஫ப்஧ாடு நதகாி஥ீர் கபப்஧ான் பத்தம் 
                     ஧ிபயநகம் ப஧ரும்஧ாடு ன௄஫஥ீர்க் யகாமய 
                அ஫ப்஧ா஦ யாயுசூம஬ யெத்துந யபாகம் 
                     ஆ஦஧஬ ஧ிணிகல௃யந யந்தடருந் தாய஦(36)”  
MARUTHUVAM:
 
In Siddha science, the treatment is not only for removal of the disease, but for 
the prevention and improving the body condition after the removal of the disease. 
This is classified as 
 Kappu    (Prevention) 
 Neekam  (Treatment) 
 Niraivu   (Restoration )  
 
KAAPU: 
It is the method of preventing the disease. Prevention Siddha principles based 
mainly on prevention as mentioned in “Theraiyar pini Annuga vithi” by Theraiyar. 
 
In “THERAIYAR PINIANUGAAVITHI” certain traditional principles of 
prevention are mentioned. In addition “SARABENDHIRAR” prescribes a few rules 
to be followed at the time of the menstruation.   
DONT’S   
  Avoid anchanam for the eyes   
  Avoid purgatives   
  Avoid heavy works   
  Avoid activities like jumping, too much of crying and laughing   
  Avoid emotional stress   
  Avoid tobacco chewing   
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  Avoid strong tea and coffee   
  Avoid fast food and spicy items   
  Avoid excess salt, spices, sweets and fat foodstuffs   
 
DO’S   
 Advice to take plenty of fibre rich foods like fruits, greens, nuts and leafy 
vegetables.   
 Advice to take Iron enriched greens, vegetables and cereals. Iron containing 
vegetables and fruit supplementation (100mg/day) prevents anaemia.   
  Vitamin C enriched diet which ensures Iron absorption and capillary 
constriction.   
  Daily consumption of dates.   
  Salt restricted diet.   
  Reducing caffeine and sugar.   
  Hip bath – Hot water hip bath as routine practice should be taken for 10mts.    
 Gentle exercises such as deep breathing exercises, progressive muscle 
relaxation, range-of-motion exercises to keep the joints mobile and slow 
relaxed walking promotes good oxygenation and circulation and can even help 
to increase energy.   
 Hygiene should be advised during menstruation.  
  
Prevention of disease is also achieved by following proper diet and good habits. 
Proper diet not only means the intake of nutritious diet but also abstinence from edible 
substances which are injurious to health.   
NEEKAM 
 
Agasthiyar kuzhambu – 100 mg with chukka kashayam should be 
administered as single dose at early morning before commencement of treatment. 
For the disease, Maampisin Chooranam -2 gms thrice a day with ghee for Day 
1 to 15 days of menstruation for 3 consecutive cycles is administrated. 
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Pathiya pathartham: 
 Proper dietic regimen enhances the effect, bioavailability of the medicine and 
helps to maintain good health. This form of medical advice in Siddha is termed as 
Pthiyam. If Pathiyam is not followed properly, certain foods may become 
incompatible and antagonise the effect of medicine and produce harmful effects to the 
body. 
Abathiya pathartham: 
“பகாள்ல௃ காடி குநட்டிக்காய் ஧ன்஫ி பகாக்குடய஦ 
 னெள்஭ிற் ப஧ாின ஧ாகற்காய் னெதிரும் அயமப ஧னற்஫ங்கால் 
  ஧ள்஭த் பதல௃ந்த நடற்யெம்ன௄ ஧டரும் யள்஭ி ஧ா஬னிமய 
஋ள்஭த் தம஦தான் தின்ன௃யபல்  ஋ல்஬ா நருந்தும் 
இமந்தீயப(37)” 
 
பகாள்ல௃, காடி, குநட்டிக்காய், ஧ன்஫ி இம஫ச்ெி, பகாக்கு, ஧ாகற்காய், 
அயமபக்காய்,  உல௃ந்து,  யெம்ன௄, ஋ள்ல௃ னெதர௅னயற்ம஫ தயிர்க்க யயண்டும். 
 
Itchaa pathiyam: 
 “கடுகு ஥ற்஫ி஬த் பதண்பணய் கூழ்஧ாண்டங்கள் கடம஬ 
            யடுய தாகின பதங்குநா யருக்மக ஥ற்கானம் 
   நடியி ஬ாதபயள் ல௃ள்஭ி பகாள்ன௄மகனிம஬ நதுப஧ண் 
                      இடர௃ ஧ாகய஬ா டகத்தி ஥ீக்கிடர௅ச் ொ஧த்தினம்(38)” 
 
கடுகு, ஥ல்ப஬ண்பணய், கடம஬, யதங்காய், நா, ஧஬ா, ப஧ருங்கானம், 
ன௅ண்டு, பகாள்ல௃, ன௄மகனிம஬, நது, ப஧ண்ய஧ாகம், ஧ாகல், அகத்தி 
னெதர௅னயற்ம஫ தயிர்க்க யயண்டும். 
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YOGASANA    
     
          Yoga helps us directly to hold physical forces in balance indirectly to develop 
mental and spiritual powers. Yoga practice tone up the pelvic organs and muscles and 
promote good circulation. Minor structural and functional defects of the body can be 
rectified by the systemic practice of Yogasanas and Pranayamas    
Women should keep in mind that they should not do asanas during their 
monthly menstrual period. After the period ends, asanas can be practiced and it will 
give a lot of benefits.   
The following aasanas are advised in menorrhagia: 
 Trikonasana  
 Vajrasana  
 Halasana  
 Patchimothasana  
 Garudasana  
 Savasana  
 Baddhakonasana  
 Sarvagasana (39) 
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YOGASANA 
 
                                                                 
 
 TRIKONASANA     VAJRASANA   
 
 
           
 HALASANA           PATCHIMOTHASANA 
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SARVANGASANA                BADDHAKONASANA 
 
 
 
     
      SAVASANA                   GARUDASANA   
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 NIRAIVU (RESTORATION): 
Physical, Psychological, social and economic rehabilitation of individual is 
known as Niraivu. 
In Pitha Perumbadu, Azhal kutram is deranged and causes impairment of 
dasavayu which in turn affect the seven Udal thathukkal. 
The line of treatment aims at bringing back the affected thaathus to normal by the 
administration of internal medicine MAAMPISIN CHOORANAM
(40)
.    
Finally assurance of the patient gives her a moral boost thereby speeding up the 
recovery.       
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MODERN ASPECT 
FEMALE REPRODUCTIVE SYTEM 
 
The female reproductive system consists of internal and external genitalia. The 
main functions of female reproductive system are  
 Production of sex hormones 
 Production of functioning gametes [ova] 
 Support & protection of developing embryo 
 
EXTERNAL GENITALIA 
The external female genitalia are referred to as vulva. It consists of the 
following structures namely, 
 Mons pubis 
 Labia majora 
 Labia minora 
 Clitoris 
 Urinary Meatus (External Urethral Orifice) 
 Hymen 
 Perineum 
The vestibule is the space into which the vagina and urethra open. The urethra 
opens just anterior to the vagina. 
The vestibule is bordered by a pair of thin, longitudinal skin folds called the 
labia minora. 
Lateral to the labia minora two prominent rounded folds of skin called the 
labia majora. 
The two labia majora unite anteriorly in an elevation of tissue over the pubic 
symphysis called the mons pubis. The lateral surface of the labia majora and the 
surface of the mons pubis are covered with coarse hair. 
The medial surface of the labia majora are covered with numerous sebaceous 
and sweat glands. The space between the labia majora is called the pudendal cleft. 
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A small erectile structure is called the clitoris is located in the anterior margin 
of the vestibule. The two labia minora unite over the clitoris to form a fold of skin 
called the prepuce
 (41)
. 
The perineum is bounded above by the inferior surface of the pelvic floor, 
below by the skin between the buttocks and thighs, laterally by the ischiopubic rami, 
ischial tuberosities and sacrotuberous ligaments and posteriorly by the coccyx
(42)
. 
 
INTERNAL GENITALIA 
The internal reproductive organs situated in the pelvis between the bladder and 
rectum. They are held in space within the pelvis by a group of ligaments. 
The internal genitalia includes 
 Vagina 
  Cervix 
 Uterus 
 Fallopian Tubes 
 Ovaries 
 
VAGINA 
 The vagina is a muscular, hollow tube that extends from the vaginal 
opening to the cervix of the uterus. It also is known as the birth canal.  
 It is a fibro muscular tube of about 10 cm long.  
 It is female organ of copulation and allows menstrual flow and child birth.  
 In young females it is covered by a thin mucous membrane called 
hymen
(43)
. 
 
CERVIX 
 The cervix is the lower, narrow portion of the uterus where it joins with 
the top end of the vagina.  
 During menstruation, the cervix stretches open slightly to allow the 
endometrium to be shed.  
 During childbirth, contractions of the uterus will dilate the cervix up to 10 
cm in diameter to allow the child to pass through
 (44)
. 
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UTERUS 
 The uterus is a hollow, pear-shaped organ which is divided into parts namely 
Cervix, which is the lower part that opens into the vagina, and the main body 
of the uterus, called the corpus. 
 The uterine wall is composed of three layers, 
 Outer serous layer or perimetrium, 
 Middle muscular layer or myometrium, 
 Innermost endometrium. 
 The endometrium consists of simple columnar epithelial cells with underlying 
connective tissue layer. The superficial part of endometrium is sloughed down 
during menstruation. 
 
POSITION OF UTERUS   
 Its normal position is anteversion and anteflexion. The uterus usually inclines 
to the right (dextrorotataion) so that the cervix is directed to the left 
(levorotation) and comes in close relation with the left ureter.  
 
MEASUREMENT OF UTERUS   
 The uterus measures about 8cm long, 5cm wide at the fundus and its walls are 
about 1.25cm thick. Its weight varies from 50-80 gm.    
 
PARTS OF THE UTERUS   
 Body or corpus  
 Isthmus  
 Cervix(45) 
 
FALLOPIAN TUBES 
 There are two uterine tubes also called uterine tubes or oviducts.  
 One uterine tube is associated with each ovary. 
  The uterine tubes extend from the ovaries to the uterus. They open pear the 
ovary to receive the oocyte and the opening is surrounded by long thin 
processes called fimbriae.  
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 As soon as oocyte is ovulated, it comes into contact with the surface of the 
fimbriae and the cilia on the fimbrial surface sweep the oocyte into the uterine 
tube.  
 Fertilization usually occurs in the uterine tube near the ovary (46). 
 
OVARIES 
 The two ovaries are small oval shaped organs attached to ligaments that 
suspend them in the pelvic cavity and from the ligament of the uterus.  
 The suspensory ligament extends from each ovary to the lateral body wall and 
the ovarian ligament attaches the ovary to the uterus.  
 A layer of visceral peritoneum called tunica albuginea covers the ovary. The 
outer cortex of the ovary is made up of dense connective tissue containing 
ovarian follicles. Each of the ovarian follicles contains an oocyte the female 
germ cell 
(47)
. 
 
PHYSIOLOGY OF MENSTRUAL CYCLE 
DEFINITION 
Menstruation is the visible manifestation of cyclic physiologic uterine 
bleeding due to shedding of the endometrium following invisible interplay of 
hormones mainly through hypothalamo-pituitary-ovarian axis. 
 For the menstruation to occur, the axis must be actively coordinated, 
endometrium must be responsive to the ovarian hormones (oestrogen and 
progesterone) and the outflow tract must be patent. 
 
DURATION OF MENSTRUAL CYCLE  
The period extending from the beginning of a period to the beginning of the 
next one is called menstrual cycle.  The first menstruation (menarche) occurs between 
11-15 years with a mean of 13 years. It is more closely related to bone age than to 
chronological age. For the past couple of decades, the age of menarche is gradually 
declining with improvement of nutrition and environmental condition.   
Once the menstruation starts, it continues cyclically at intervals of 21-35 days 
with a mean of 28 days.  
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Physiologically, it is kept in abeyance due to pregnancy and lactation. 
Ultimately, it ceases between the age 45-50 when menopause sets in.  
The duration of menstruation is about 4-5 days and the amount of blood loss is 
estimated to be 20-80ml with an average of 35ml. Nearly 70% of total menstrual 
blood loss occurs in the first 2 days.  
 
CONTENTS OF MENSTRUAL DISCHARGE   
 The menstrual discharge consists mainly of dark altered blood, mucus, 
vaginal epithelial cells and fragments of endometrium, prostaglandins, enzymes and 
bacteria 
(48)
. 
     
MENSTRUAL SYMPTOMS  
 In majority, apart from bleeding from vagina there is no symptom. Initially, it 
begins as pink discharge but on day 2 and 3 it becomes dark red.  
In teenagers or nulliparous, there may be associated tolerable colicky pain at 
the beginning due to uterine contraction.  
If the pain is of sufficient magnitude so as to incapacitate the day-today 
activities, it is called dysmenorrhoea.  
 
There may be premonitory symptoms such as   
 Pelvic discomfort    
 Backache    
 Fullness of the breasts or mastalgia   
 Headache or depression   
 Constipation or diarrhoea   
 Appetite changes or food carvings   
 Irritability or mood swings   
These symptoms are predominant and grouped into a syndrome called 
Premenstrual syndrome 
(49)
.  
 
CHANGES DURING MENSTRUAL CYCLE  
During each menstrual cycle, series of changes occur in ovary, uterus, vagina 
and cervix.    
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OVARIAN CHANGES DURING MENSTRUAL CYCLE  
 It occurs in two phases, which includes  
 Follicular phase   
 Luteal phase   
 
UTERINE CHANGES DURING MENSTRUAL CYCLE   
Along with ovarian changes, uterine changes also occur simultaneously. This 
changes in uterus takes place in three phases which includes    
 Menstrual phase    
 Proliferative phase   
 Secretory phase 
 
CHANGES IN VAGINA AND CERVIX DURING MENSTRUAL CYCLE   
 Proliferative phase   
 Secretory phase(50) 
 
PHASES OF MENSTRUAL CYCLE
 
The day count for menstrual cycle begins on the first day of menstruation 
when blood starts to come out of the vagina. In this section, the length of menstrual 
cycle has been assumed to be 28 days (which is the average among women). The 
entire duration of a menstrual cycle can be divided into four main phases: 
 
1. Menstrual phase (From day 1 to 5) 
2. Follicular phase (From day 1 to 13) 
3. Ovulation phase (Day 14) 
4. Luteal phase (From day 15 to 28) 
 
MENSTRUAL PHASE (day 1-5) 
Menstrual phase begins on the first day of menstruation and lasts till the 5th 
day of the menstrual cycle.  
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The following events occur during this phase: 
 The uterus sheds its inner lining of soft tissue and blood vessels which exits 
the body from the vagina in the form of menstrual fluid. 
 Blood loss of 10 ml to 80 ml is considered normal. 
 This phase is also known as destructive phase or phase of bleeding. 
 During this phase, the uterus sheds its inner lining of soft tissue and blood 
vessels which exits the body from the vagina in the form of menstrual fluid. 
 
FOLLICULAR PHASE (day 1-13) 
This phase also begins on the first day of menstruation, but it lasts till the 13th 
day of the menstrual cycle. This phase is also known as preovulatory phase or 
proliferative phase or oestrogen phase. The following events occur during this phase: 
 The pituitary gland secretes a hormone that stimulates the egg cells in the 
ovaries to grow. 
 One of these egg cells begins to mature in a sac-like-structure called follicle. It 
takes 13 days for the egg cell to reach maturity. 
 While the egg cell matures, its follicle secretes a hormone that stimulates the 
uterus to develop a lining of blood vessels and soft tissue called endometrium. 
 
OVULATION PHASE (day 14) 
On the 14th day of the cycle, the pituitary gland secretes a hormone that 
causes the ovary to release the matured egg cell. The released egg cell is swept into 
the fallopian tube by the cilia of the fimbriae. Fimbriae are finger like projections 
located at the end of the fallopian tube close to the ovaries and cilia are slender hair 
like projections on each Fimbria. 
 
LUTEAL PHASE (day 15-28) 
This phase begins on the 15th day and lasts till the end of the cycle. This phase is 
also known as secretory phase. The following events occur during this phase: 
 The egg cell released during the ovulation phase stays in the fallopian tube for 
24 hours. 
 If a sperm cell does not impregnate the egg cell within that time, the egg cell 
disintegrates. 
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 The hormone that causes the uterus to retain its endometrium gets used up by 
the end of the menstrual cycle. This causes the menstrual phase of the next 
cycle to begin 
(51)
. 
 
HORMONES REGULATING THE CYCLE: 
A normal menstrual cycle depends on cyclical ovarian steroid secretions which in 
turn are controlled by the pituitary and the hypothalamus and to some extent by the 
thyroid and adrenal glands. So the hypothalamo-pituitary-ovarian axis is important. 
The following hormones play the major role,   
 Gonadotropin releasing hormone (GnRH) 
  Follicle stimulating hormone (FSH)   
  Luteinising hormone (LH)   
  Oestrogen   
 Progesterone. 
 
GONADOTROPIN RELEASING HORMONE (GnRH):  
Gonadotropin releasing hormone is secreted by the hypothalamus which 
modulates the neural control of FSH and LH by the anterior pituitary.  GnRH is 
released in a pulsatile manner.  In preovulatory phase, it pulses every 60 minutes but 
slows down in luteal phase to one in 3 hours. GnRH is continuous in males but 
pulsatile in females.  The hypothalamus is controlled by higher cortical centers 
(temporal lobe). Emotional upsets stimulate or depress the H-P-O axis and disturb the 
menstrual cycles. 
 
ANTERIOR PITUITARY HORMONE 
FOLLICLE STIMULATING HORMONE (FSH)   
It is secreted by the beta cells of anterior pituitary gland. FSH controls the 
ripening of the primordial follicles and in combination with the luteinizing hormone 
activates the secretion of oestrogen.  Its action starts after cease of menstruation and 
reaches the peak by 7th day and then declines to disappear around 18th day. Another 
small peak occurs in the premenstrual phase.  Low FSH causes defective 
folliculogenesis and short or defective corpus luteal phase. 
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 LUTEINIZING HORMONE (LH) 
It is secreted by the beta cells of anterior pituitary gland. In combination with 
FSH it activates the secretion of oestrogen.  
It brings about maturation of the ovum and causes ovulation.  
LH stimulates the completion of the reduction division of the oocyte. 
Following ovulation it produces luteinization of the granulosa and the theca cells and 
initiates progesterone secretion.  
The LH surge precedes ovulation by 24 to 36 hours. 
 
OVARIAN HORMONES 
 
OESTROGEN   
The main sources of oestrogen are the theca end granulosa cells of the graafian 
follicles and corpus luteum, while the adrenal cortex is the secondary source.  
Its level rises 6 to 7 days before ovulation and reaches the peak 2 days before 
ovulation and then declines.  
It increases uterine vascularity and regenerates the endometrium after 
menstruation and is responsible for the proliferative hyperplasia of the endometrium. 
  
PROGESTERONE 
The corpus luteum is the main source of progesterone. The level rises after 
ovulation and reaches peak at mid luteal phase. With the degeneration of the corpus 
luteum its level falls and brings about menstruation.  
If pregnancy occurs the corpus luteum continues to enlarge and secrete 
progesterone.  
The high level of the hormone prevents menstruation and leads to 
amenorrhoea of pregnancy 
(52)
. 
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                                                    MENORRHAGIA 
SYNONYM 
                        Hyper-menorrhea  
Menostaxis 
DEFINITION 
Menorrhagia is defined as cyclic bleeding at normal intervals. The bleeding is 
either excessive in amount (>80ml) or duration or both. The term Menostaxis is often 
used to denote prolonged bleeding. 
 
CAUSES 
Menorrhagia has some underlying pathology- organic or functional.   
ORGANIC CAUSES   
  Pelvic    
  Systemic   
  Endocrinal   
  Blood dyscrasias   
  Emotional upset  
PELVIC PATHOLOGY   
Due to congestion, increased surface area or hyperplasia of the endometrium.    
  Fibroid uterus   
  Fibroid polyp   
  Adenomyosis   
  Chocolate cyst   
  PCOD   
  Pelvic endometriosis   
  IUCD    
  Chronic tubo-ovarian mass   
  Tubercular endometritis (early cases)   
 Pelvic inflammatory diseases   
  Retroverted uterus – due to congestion   
  Granulosa cell tumour of the ovary  
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SYSTEMIC CAUSES   
  Congestive cardiac failure    
  Severe hypertension  
ENDOCRINAL CAUSES   
  Hypothyroidism   
 Initial stages of Hyperthyroidism   
BLOOD DYSCRASIAS   
  Idiopathic thrombocytopenic purpura   
  Leukaemia   
  Von Willebrand‘s disease   
  Platelet deficiency (thrombocytopenia)  
 
FUNCTIONAL CAUSES   
Due to disturbed hypothalamo- pituitary- ovarian- endometrial axis    
 
COMMON CAUSES OF MENORRHAGIA   
  Dysfunctional uterine bleeding   
  Fibroid uterus   
  Adenomyosis   
  Chronic tubo-ovarian mass  
 
PATHO –PHYSIOLOGY   
The current concept concludes that the abnormal bleeding is most likely due to 
local causes in the endometrium. There is some disturbance of the endometrial blood 
vessels and capillaries and coagulation of blood in and around blood vessels. These 
are probably related to alteration in the ratio of endometrial prostaglandins which are 
delicately balanced in haemostasis of menstruation.  
The endometrial abnormalities may be primary or secondary to inco-
ordination in the hypothalamo-pituitary-ovarian axis. It is thus more prevalent in 
extremes of reproductive period – adolescence and premenopause or following 
childbirth and abortion.  
Emotional influences, worries, anxieties or sexual problems sometimes are 
enough to disturb the normal hormonal balance 
(53)
. 
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SYMPTOMS OF MENORRHAGIA 
 Saturating multiple sanitary pads or tampons per hour 
 Requiring two sanitary pads to contain uterine bleeding 
 Waking up at night to change sanitary pads or tampons 
 Prolonged bleeding that lasts beyond a week 
 Passing large blood clots 
 Inability to engage in routine daily activities 
 Fatigue and weakness (signs of anaemia) 
 Tiredness 
 Shortness of breath 
 Headache 
 Lower abdominal pain 
 
INVESTIGATIONS 
 
 Blood tests 
       A sample of blood may be evaluated for iron deficiency (anaemia) and 
other conditions, such as thyroid disorders or blood-clotting abnormalities. 
 Pap test 
       In this test, cells from the cervix are collected and tested for infection, 
inflammation or changes that may be cancerous or may lead to cancer. 
 Endometrial biopsy 
       Take a sample of tissue from the inside of the uterus to be examined by 
a pathologist. 
 Ultrasound scan  
        This imaging method uses sound waves to produce images of the 
uterus, ovaries and pelvis. 
Based on the results of the initial tests, doctor may recommend further testings, 
including: 
 Sonohysterography 
               During this test, a fluid is injected through a tube into the uterus by 
way of vagina and cervix and then uses ultrasound to look for problems in the 
lining of the uterus. 
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 Hysteroscopy 
                This exam involves inserting a tiny camera through the vagina and 
cervix into the uterus, which allow to seeing inside of the uterus. 
 
MANAGEMENT  
 General measures to improve the health status of the patient. Advice regarding 
proper diet, adequate rest during menses, oral administration of haematinics, 
vitamins and protein supplements and to maintain a menstrual calendar noting 
duration and extent of blood loss.   
 Treat the cause.    
 
 
In women suffering from DUB, consider: 
 Oral non-steroidal anti-inflammatory drugs like mefenamic acid 500 mg t.d.s 
along with antacids. Other drugs in the category include naproxen, ponstan 
and ibuprofen   
 Cyclic oral contraceptive pills.     
 Oral progesterone - When taken for 10 or more days of each menstrual cycle, 
the hormone progesterone can help correct hormone imbalance and reduce 
menorrhagia.   
 The hormonal IUD (Mirena) - This intrauterine device releases a type of 
progestin called levonorgestrel, which makes the uterine lining thin and 
decreases menstrual blood flow and cramping.   
 Hysterectomy in selected cases.  
 
THERAPEUTIC MEASURES   
This includes   
 Removal of an offending intrauterine contraceptive device.   
 Myomectomy or hysterectomy for uterine fibroids.   
 Wedge resection or hysterectomy for adenomyosis of the uterus.   
 Laparoscopic lysis of adhesions for chronic PID.   
 Electrocautery or laser vaporization of endometriosis and drainage of 
chocolate cysts in pelvic endometriosis.   
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 Hysterectomy with or without removal of the adnexa as per the age and the 
individual needs of the patient.   
 In patients suffering from bleeding disorders, a haematologist‘s opinion should 
be sought 
(54)
.  
 
Dilation and curettage (D&C)   
In this procedure, opens (dilates) cervix and then scrapes or suctions tissue 
from the lining of uterus to reduce menstrual bleeding. Although this procedure is 
common and often treats acute or active bleeding successfully, may need additional 
D&C procedures if menorrhagia recurs. 
 
Uterine artery embolization  
For women whose menorrhagia is caused by fibroids, the Goal of this 
procedure is to shrink any fibroids in the uterus by blocking the uterine arteries and 
cutting off their blood supply. 
During uterine artery embolization, the surgeon passes a Catheter through the 
large artery in the thigh (femoral artery) and guides the uterine arteries, where the 
blood vessel is injected with microspheres made of plastic. 
 
Focused ultrasound ablation 
Similar to uterine artery embolization, focused ultrasound ablation treats 
bleeding caused by fibroids by shrinking the fibroids. This procedure uses ultrasound 
waves to destroy the fibroid tissue. There are no incisions required for this procedure. 
Myomectomy 
This procedure involves surgical removal of uterine fibroids depending on the 
size, number and location of the fibroids. 
Endometrial ablation  
Using a variety of techniques permanently destroys the lining of the uterus 
(endometrium). After endometrial ablation, most women have much lighter periods.  
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Endometrial resection 
This surgical procedure uses an electrosurgical wire loop to remove the lining 
of the uterus. Both endometrial ablation and endometrial resection benefit women 
who have very heavy menstrual bleeding.  
Hysterectomy 
Hysterectomy is a surgical operation to remove the uterus and cervix. It is a 
permanent procedure that causes sterility and ends menstrual periods 
COMPLICATIONS 
 Iron deficiency anaemia 
 Tiredness 
 Psychological disturbances 
 Poor concentration (55). 
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CROSS  SECTION  OF  INTERNAL  GENITAL  ORGANS 
               
 
 
          
 CROSS  SECTION  OF  OVARY  SHOWING  ITS  LIFE CYCLE 
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MENSTRUAL CYCLE 
 
  
 
 
 
 
 
TRIAL  MEDICINE 
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TRIAL MEDICINE 
MAAMPISIN CHOORANAM 
INGREDIENTS: 
Nattu Maampisin (Mangifera indica)                   : 35 gm 
Nelli vattral ( Phyllanthus emblica)                    : 35 gm 
Panangkarkandu ( Borassus flabellifer )                     : 35 gm 
 
STANDARD OPERATING PROCEDURE 
SOURCE OF RAW DRUGS: 
The required raw drugs were obtained from a well reputed indigenous raw drug 
shop. The raw drugs taken for the study were authenticated by the Central Council of 
Research Institute of Siddha, Chennai, 600106. 
PURIFICATION OF RAW DRUGS: 
Raw drugs were purified as mentioned in Sikitcha Ratna Deepam Sarakku Suthi 
Muraigal. 
PREPARATION: 
The above given drugs were purified and grinded, then sieved it by using cloth 
and preserved it in air tight container as mentioned in the literature. 
DRUG STORAGE: 
      The trial drug was stored in clean dry air tight container and it was dispensed to 
the patients in pockets. 
DOSE                  :    2 gm , tds (After food) 
ADJUVENT       :    Ghee 
DURATION       :    1 to 15 days of menstruation for 3 consecutive cycles. 
REFERENCE    :    Siddha Vaidhiya  Pathartha Guna Vilakkam-Moola Varkkam                        
                       Page No 596
(56)
. 
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LITERATURE REVIEW OF TRIAL DRUGS: 
1. Maampisin : 
 
Botanical Name :    Mangifera indica 
Family   :   Anacardiaceae 
Suvai   :   Thuvarppu 
Thanmai  :   Thatpam 
Pirivu   :   Kaarppu
(57) 
Action   :   Astringent, Sedative
(58) 
Chemical Components:   Tannins 
        Polyphenolics 
        Flavonoids 
        Triterpenoids 
        Mangiferin
(59) 
ப஧ொதுகுணம்: 
  ப஧ரும்஧ொபெங்   கேபத்தப்   க஧திபனங்   கேமுக்ேல் 
  தரும்஧ொழும்   பெள்ள஭பனங்கே   சொற்஫ொய் –  ேரும்஧ொம்஧ின் 
  ஥ொத஥ிொி   னொசஞ்பசய்   ஥ங்ேொய் !   ெ஦த்திலுள஫ 
  சூத஥ிொி   னொசபந஦ச்  பசொல்(60). 
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2. Nellivattral : 
 
Botanical Name :    Phyllanthus emblica 
Family   :   Phyllanthacee 
Suvai   :   Pulippu, Thuvarppu, Inippu, 
Veeryam  :   Thatpam 
Pirivu   :   Inippu 
Action   :   Astringent,  
Chemical Components:  Tannins 
    Flavonoids 
    Alkaloids  
    Phenolic compounds  
    Amino acids 
    Carbohydrates 
       Chebulinic acid
(61) 
ப஧ொதுகுணம்: 
  ஆேெ஦   ஬ஞ்சசிஅ   சிர்க்பேன்பு   ருக்ேிேண்கணொய் 
  தொே    முதிபெித்தந்   தொது஥ஷ்ெம் -   கநே஦த்தின் 
  இல்லிமுள்஭ி   க஧ொ஬ருேல்   எண்஬ேொ   நினெினங்ேம் 
  ப஥ல்லிமுள்஭ி   னொற்க஧ொ   ஥ிள஦(62) 
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3. Panangarkandu: 
 
Botanical Name :     Borassus flabellifer  
Family   :     Arecaceae 
Suvai   :     Inippu 
Thanmai  :     Thatpam 
Pirivu   :     Inippu 
Action   :     Refrigerant 
(63) 
Chemical Components:     Phenolic compounds, Potassium, 
       Iron, Phosphorus 
(64) 
 
MAAMPISIN CHOORANAM 
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MATERIALS AND METHODS 
 
STUDY DESIGN: 
The clinical trial on Pitha Perumbadu (Menorrhagia) was decided to conduct 
as an open label study.  
The study was approved by Institutional Ethics Committee (IEC) and the 
approved number is GSMC –CH – ME -5/003/2016. The study was registered in 
Clinical Trials Registry – India (CTRI) and the reference Number is 
CTRI/2018/03/012381. 
 
STUDY CENTRE:   
The entire study was conducted on patients at Out Patients Department of 
Government Siddha Medical College, Chennai in the premises of Arignar Anna 
Government Hospital for Indian Medicine and Homeopathy, Arumbakkam, Chennai – 
106, during the period of 2016-2018.  
 
POPULATION:   
The population consists of all patients were attending the OPD of Arignar 
Anna Hospital, Arumbakkam, Chennai – 106. Sample consists of Pitha Perumbadu 
who satisfying the inclusion and exclusion criteria mentioned below:  
 
SAMPLE SIZE: 
                30 patients  
 
STUDY DRUG: 
 Maampisin Chooranam – 2 gm thrice a day with Ghee for Day 1 of 
menstruation to 15 days for 3 consecutive cycles. 
 
SELECTION CRITERIA: 
               The population of pitha perumbadu rogam patients with the following signs 
and symptoms are taken into the clinical trial. 
 Age 15 – 50 years 
 Excessive menstruation  
 Prolonged menstruation  
 Presence of blood clots in menstrual bleeding  
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 Lower abdominal pain  
 Low back ache  
 Giddiness during menstruation  
 Headache during menstruation  
 Tiredness during menstruation  
 USG report with fibroid uterus or PCOD. 
 
EXCLUSION CRITERIA:     
 Chocolate Cysts                  
 Adenomyosis                
 Bleeding Disorders    
 Hypothyroidism 
 Ovarian Feminizing Tumors 
 Abortion and Pregnancy  
 Uterine Cancer 
 Patient having IUCD  
 Thrombocytopenic purpura   
 Coagulopathy  
 Severe anaemia (<6 gm)  
 Vulnerable populations such as  
HIV positive  
TB affected individuals 
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of any serious adverse 
effect during trial (if ADR is reported, it should be informed to 
SCRI) and the patient is directed to nearest Govt. Hospital. 
 Patient turned unwilling to continue in the course of clinical trial.  
 Poor compliance 
 Any other acute illness which needs a rescue medication. 
 
 
 
 
                                                                                 MATERIALS AND METHODS 
 
An open non-randomized clinical trial of Maampisin Chooranam in Pitha Perumbadu Page 58 
 
EVALUATION OF CLINICAL PARAMETERS: 
Patients are clinically evaluated by the following parameters. 
A. HISTORY TAKING: 
              Age, Occupation, Socio economic status, Complaints and its duration, 
previous illness, Family history, Personal habits, menstrual history were recorded in 
the case sheet for every patient at the time of first visit to the OP. 
 
B. INVESTIGATIONS: 
              All the patients were subjected to the laboratory investigations before and       
after treatment. 
 BLOOD: 
             TC, DC, ESR, Hb, Blood Sugar ( R ), Serum cholesterol, 
Blood Urea, Serum Creatinine, Bleeding time and Clotting time. 
 URINE: 
Albumin, Sugar, Deposits. 
 USG FOR WHOLE ABDOMEN & PELVIS. 
 
  ASSESSMENT OF MENSTRUAL BLOOD LOSS:   
              Reduction of blood flow was assessed by  
 Number of sanitary pad used before and after treatment  
 Based on Pictorial Blood loss Assessment Chart (PBAC) before 
and after treatment. 
 
SIDDHA ASSESSMENTS:  
 Envagai thervugal  
 Neerkuri  
 Neikkuri  
A case sheet format was prepared on the basis of the Siddha methodology ex: 
Envagai thervvugal, Mukkutram, Nilam, Kaalam, Udal thathukkal, Neerkuri and 
Neikuri. Individual case sheet was maintained for each patient at outpatient 
department.   
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RESULTS AND OBSERVATION 
Pitha Perumbadu Rogam was carried out and analysed in 30 patients in the 
OPD Post Graduate Pothu Maruthuvam Department, Government Siddha Medical 
College, Chennai-106 attached to Arignar Anna Government Hospital of Indian 
Medicine during 2016 - 2018. The observations were made and tabulated with 
following criteria:   
 Distribution of Age  
 Occupational Distribution  
 Distribution of Marital status  
 Distribution of Socio-economic status  
 Distribution of Food habits  
 Distribution of Paruvakkalam  
 Distribution of Thinai  
 Distribution of Mukkutram  
- Vathakutram           
- Pittha kutram            
- Kabha kutram  
 Distribution of Udal Thaathukal  
 Distribution of Envagai thervugal              
 Signs and Symptoms before and  after treatment  
 Number of pads used before and after treatment  
 Hemoglobin level before and after treatment  
 Bleeding time and Clotting time before and after treatment  
 Gradating of results.      
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1. AGE DISTRIBUTION 
S.NO AGE NO. OF CASES PERCENTAGE (%) 
1 15-25 YEARS 4 13% 
2 26-35 YEARS 3 10% 
3 36-45 YEARS 12 40% 
4 46-50 YEARS 11 37% 
 
  
 
INFERENCE: 
According to the above mentioned data, 40% of Patients in the age group of 
36-45 years were mostly affected, 37% of patients were in the age group of 46-50 
years. 13% of patients were in the age group of 15-25, 10% of patients were in the age 
group of 26-35 Years. 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
15-25 Years 26-35 Years 36-45 Years 46-50 Years
AGE DISTRIBUTION 
                                                                           RESULTS AND OBSERVATION 
 
An open non-randomized clinical trial of Maampisin Chooranam in Pitha Perumbadu Page 61 
 
2. OCCUPATIONAL STATUS 
 
S.NO 
 
  NATURE OF WORK 
 
NO.OF CASES 
 
PERCENTAGE (%) 
 
    1. 
 
       STUDENT 
 
2 
 
7% 
 
    2. 
 
 
      WORKING WOMEN 
 
 
9 
 
 
30% 
 
 
    3. 
 
       HOUSE WIFE 
 
19 
 
63% 
   
 
 
INFERENCE  
Among 30 patients, 19 patients (63%) were house wifes, 9 patients (30%) were 
working women and 2 patients (7%) were students.    
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3. MARITAL STATUS 
S.NO STATUS NO OF CASES PERCENTAGE 
1 UNMARRIED 3 10% 
2        MARRIED 27 90% 
 
 
 
INFERENCE  
Among 30 cases, 27 patients (90%) were married and 3 patients (10%) were 
unmarried.      
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4. SOCIO-ECONOMIC STATUS 
S.NO STATUS 
INCOME  PER ANNUM 
NO.OF CASES PERCENTAGE 
    
    1. 
      
      LOWER 
      (BELOW 2 LAKHS) 
           
            13 
        
           43% 
     
    2. 
           
     MIDDLE 
     (UPTO 2 LAKHS) 
           
            12 
 
           40% 
     
    3. 
             
     UPPER 
     (ABOVE 5 LAKHS) 
           
             5 
 
           17% 
 
 
INFERENCE  
                  Out of 30 patients, 13 patients (43%) were from lower income group, 12 
patients (40%) were from middle income group and 5 patients (17%) were from upper 
income group.    
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5. FOOD HABITS 
 
S.NO 
 
FOOD HABITS 
 
NO.OF CASES 
 
PERCENTAGE 
 
1. 
 
VEGETARIAN 
 
17 
 
57% 
 
2. 
 
MIXED DIET 
 
13 
 
43% 
 
 
 
INFERENCE 
                   Among 30 patients, 13 patients (43%) were taking mixed diet and 17 
patients (57%) were taking vegetarian diet. 
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6. PARUVAKALAM 
S.NO          KAALAM NO. OF  CASES PERCENTAGE 
      
     1. 
     KAAR KAALAM 
     (AUG16-OCT15) 
 
0 
 
0% 
      
     2. 
   KOOTHIR KAALAM 
    (OCT16-DEC15) 
 
0 
 
0% 
      
     3. 
  MUNPANI KAALAM 
    (DEC16-FEB15) 
 
12 
 
40% 
     
     4. 
  PINPANI KAALAM 
    (FEB16-APR15) 
 
18 
 
60% 
 
     5. 
  ELAVENIL KAALAM 
   (APR16-JUN15) 
 
0 
 
0% 
 
     6. 
  MUTHUVENIL KAALAM 
   (JUN16-AUG15) 
 
0 
 
0% 
 
 
 
INFERENCE: 
Among 30 patients, 18 patients (60%) were reported in Pinpani Kaalam, 12 
patients (40%) were reported in Munpani Kaalam. 
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7. THINAI 
 
S.NO 
           
            THINAI 
 
NO.OF CASES 
 
PERCENTAGE 
 
1. 
 
           KURINJI 
 
0 
 
0% 
 
2. 
 
           MULLAI 
 
0 
 
0% 
 
3. 
 
           MARUTHAM 
 
1 
 
3% 
 
4. 
 
          NEITHAL 
 
29 
 
97% 
 
5. 
 
          PAALAI 
 
0 
 
0% 
    
        
INFERENCE  
                  Among 30 patients, 29 patients (97%) were from Neithal thinai and 1 
patient (3%) was from Marutham thinai.  
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 8.  MUKKUTRAM 
a. VATHA KUTTRAM 
S.NO TYPES OF VATHAM NO.OF CASES PERCENTAGE 
      1.            PRANAN 6 20% 
      2.            ABANAN 30 100% 
      3.            UDHANAN 3 10% 
      4.            VIYANAN 30 100% 
      5.            SAMAANAN 12 40% 
      6.            NAAGAN 0 0% 
      7.            KOORMAN 2 7% 
      8.            KIRUGARAN 0 0% 
      9.            DEVATHATHAN 30 100% 
      10.            THANANJAYAN 0 0% 
 
 
 
 
 
 
INFERENCE  
                    Out of 30 patients,  Abanan,Viyanan and Devathathan  were affected in 
all the 100% of patients, Koorman  was affected in 7% of patients, Pranan was 
affected in 20% of patients and Samanan was affected in 40% of patients. 
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a. PITHAKKUTRAM 
 
 
S.NO 
 
TYPES OF PITHAM 
 
NO.OF CASES 
 
PERCENTAGE 
     1.        ANALAGAM             12             40% 
     2.        RANJAGAM             30             100% 
     3.        SAATHAGAM             30             100% 
     4.        PRASAGAM             27             90% 
     5.        ALOSAGAM            2             7% 
 
 
INFERENCE 
                 Out of 30 patients, Saathagam and Ranjagam were affected in all the 100% 
of patients, Prasagam was affected in 90% of patients, Alosagam was affected in 7% 
of patients and Analagam was affected in 40% of patients. 
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c. KABHAKUTTRAM 
 
 
S.NO 
 
TYPES OF KABHAM 
 
NO.OF CASES 
 
PERCENTAGE 
    1.         AVALAMBAGAM              0             0% 
    2.         KILETHAGAM              12             40% 
    3.         POTHAGAM              0             0% 
    4.         THARPAGAM              3             10% 
    5.         SANTHIGAM              20             67% 
 
 
 
 
INFERENCE 
 
                        Among 30 patients, Santhigam was affected in 67% of patients, 
Kilethagam was affected in 40% of patients and Tharpagam was affected in 10% of 
patients. 
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9. DEFECTS IN UDALTHATHUKKAL 
 
S.NO 
 
UDAL THATHUKKAL 
 
NO.OF CASES 
 
PERCENTAGE 
1.     SAARAM 30 100% 
2.     SENNEER 30 100% 
3.     OON 0 0% 
4.     KOZHUPPU 0 0% 
5.     ENBU 20 67% 
6.     MOOLAI 0 0% 
7.     SURONITHAM 30 100% 
 
 
 
INFERENCE 
                     Out of 30 patients, Saaram and Suronitham were affected in all the 30 
patients (100%), Senneer was affected in 25 patients (83%) and Enbu was affected in 
20 patients (67%). 
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10. EN VAGAI THERVUGAL 
 
S.NO 
           ENVAGAI  
        THERVUGAL                                 
 
NO.OF CASES 
 
PERCENTAGE 
1. NAADI 30 100% 
2. SPARISAM 0 0% 
3. NAA 27 90% 
4. NIRAM 15 50% 
5. MOZHI 0 0% 
6. VIZHI 29  97% 
7. MALAM 6 20% 
8 MOOTHIRAM 1 3% 
 
 
INFERENCE  
                       Among 30 patients, Naadi was affected in all the 30 patients (100% ), 
Vizhi was affected in 29 patients (97%), Naa was affected in 27 patients (90%),  
Niram affected in 15 patients (50%), Malam was affected in 6 patients (20%) and 
Moothiram was affected in 1 patient (3%). 
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NAADI 
 
 
 
S.NO 
 
              NAADI 
 
NO.OF CASES 
 
PERCENTAGE 
 
    1 
 
      PITHA VATHAM 
 
              19 
 
            63% 
 
    2 
 
      VATHA PITHAM 
 
              11 
 
            37% 
 
 
 
INFERENCE 
          Among 30 patients, 19 patients (63%) had Pitha Vatha naadi and 11 patients 
(37%) had Vadha Pitha naadi. 
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NEIKURI 
 
 
S.NO 
 
THATHU 
 
NEIKURI 
 
NO.OF CASES 
 
PERCENTAGE 
 
1. 
 
Vatham 
 
Spread Like Snake 
 
7 
 
23% 
 
2. 
 
Pitham 
 
Spread Like Ring 
 
23 
 
77% 
3 Kabham Spread like pearl 0 0% 
 
 
 
 
INFERENCE 
Among the urine sample of 30 patients, 23 samples (77%) show Pitha neer and 
7 samples (23%) show Vatha neer.  
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11. SIGNS AND SYMPTOMS 
 
 
S. 
NO 
 
 
SIGNS AND SYMPTOMS 
BEFORE              
TREATMENT 
AFTER      
TREATMENT 
NO.OF 
CASES 
PERCE
NTAGE 
NO.OF 
CASES 
PERCEN
TAGE 
1. Excessive Menstruation 26 87% 2 7% 
2. Prolonged Menstruation           17 57% 1 3% 
3 Presence Of Blood Clots 21 70% 0 0% 
3. Lower Abdominal Pain 10 33% 0 0% 
4. Low Back Ache 11 37% 3 10% 
5. Tiredness 27 83% 5 17% 
6. Giddiness 16 53% 0 0% 
7. Head Ache 4 13% 0 0% 
 
INFERENCE 
              Excessive menstrual bleeding after treatment were drawn from 87% to 7%, 
prolonged menstrual bleeding were drawn from 57% to 3%, presence of blood clots 
were drawn from 70% to 0%,lower abdominal pain were drawn from 33% to 0%,Low 
back ache were drawn from 37% to 10%, Tiredness were drawn from 83% to 17%, 
giddiness from 53% were drawn to 0%, Headache from 13% were drawn to 0%. 
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12. NUMBER OF PADS 
 
BEFORE TREATMENT 
 
S.NO 
 
NO.OF PADS/ CYCLE NO.OF CASES 
 
PERCENTAGE 
 
 
1 
 
ABOVE 25 PADS 
 
12 
 
40% 
 
 
2 
 
21 - 25 PADS 
 
13 
 
43% 
 
 
3 
 
16 - 20 PADS 
 
5 
 
17% 
 
 
4 
 
BELOW 16 PADS 
 
0 
 
0% 
 
 
 
 
AFTER TREATMENT 
 
S.NO 
 
NO.OF PADS/CYCLE NO.OF CASES PERCENTAGE 
 
1 
 
ABOVE 25 PADS 
 
1 
 
3% 
 
 
2 
 
21 - 25 PADS 
 
2 
 
7% 
 
 
3 
 
16 - 20 PADS 
 
6 
 
20% 
 
 
4 
 
BELOW 16 PADS 
 
21 
 
70% 
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 NUMBER OF PADS BEFORE AND AFTER TREATMENT 
 
 
 
 
 INFERENCE  
                              After treatment, patients using above 25 pads were drawn from 
40% to 3%, the patients using 21-25 pads were drawn from 43% to 7%, the patients 
using 16-20 pads were drawn from 17% to 20% and the patients using below 16 pads 
were increased from 0 to 70%. 
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13.  CLINICAL PROGNOSIS 
MENSTURAL BLOOD LOSS ASSESSMENT SCORE 
S.NO OP.NO 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
PROGNOSIS 
1 4819 335 95 Good 
2 684 295 145 Moderate 
3 8610 276 180 Mild 
4 891 340 80 Good 
5 124 350 100 Good 
6 2768 323 95 Good 
7 8802 355 185 Mild 
8 5812 250 95 Good 
9 3196 405 125 Moderate 
10 1004 402 100 Good 
11 3663 211 98 Good 
12 3797 285 95 Good 
13 8539 265 100 Good 
14 3842 308 85 Good 
15 825 295 135 Moderate 
16 6713 213 90 Good 
17 6942 305 100 Good 
18 2756 284 100 Good 
19 5585 295 90 Good 
20 7293 272 100 Good 
21 5007 225 130 Moderate 
22 728 230 95 Good 
23 4927 360 140 Moderate 
24 6610 200 95 Good 
25 8665 230 100 Good 
26 8404 275 95 Good 
27 5582 320 90 Good 
28 320 420 300 Mild 
29 7497 310 99 Good 
30 1397 355 145 Moderate 
Note: Improvement is assessed by based on the PBAC (Pictorial Blood loss 
Assessment Chart) score 
≤ 100     :   Good Improvement   
101 – 150   :   Moderate Improvement   
> 150   :   Mild Improvement 
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14.. HAEMATOLOGICAL OBSERVATION 
BEFORE TREATMENT 
 
S.NO 
 
HAEMOGLOBIN LEVEL 
 
NO.OF CASES 
 
PERCENTAGE 
1 > 12 gm/ dl 0 0% 
2 10 - 12 gm/dl 9 30% 
3 8 - 10 gm/dl 15 50% 
4 < 8  gm/dl 6 20% 
AFTER TREATMENT 
 
S.NO 
 
HAEMOGLOBIN LEVEL 
 
NO.OF CASES 
 
PERCENTAGE 
1 > 12 gm/ dl 1 3% 
2 10 - 12 gm/dl 18 60% 
3 8 - 10 gm/dl 9 30% 
4 < 8  gm/dl 2 7% 
  
 
 
INFERENCE  
                      After treatment 12-15 gms of Hb were about 3%, 10-12 gms of Hb were 
about 63%, 8-10 gms of Hb were about 30% and 6-8 gms of Hb were about 7%. 
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GRADATION OF RESULTS 
 
 
S.NO 
 
GRADE OF RESULTS 
 
NO.OF CASES 
 
PERCENTAGE 
 
1. 
 
  GOOD RESPONSE 
 
21 
 
70% 
 
2. 
 
  MODERATE RESPONSE 
 
6 
 
20% 
 
3 
 
  MILD RESPONSE 
 
3 
 
10% 
 
 
 
INFERENCE 
                            Good response of treatment was about 70%, moderate response of 
treatment was about 20% and mild response was in 10% of the patients. 
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NUMBER OF PADS USED BY THE PATIENTS 
                                            BEFORE AND AFTER TREATMENT   
 
S. 
NO 
OP. NO PATIENT’S 
AGE 
NUMBER OF PADS FOR A CYCLE 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
1 4819 38 21 9 
2 684 28 32 20 
3 8610 48 26 21 
4 891 37 22 8 
5 124 23 30 10 
6 2768 45 20 9 
7 8802 17 39 21 
8 5812 28 21 13 
9 3196 22 28 16 
10 1004 30 25 14 
11 3663 44 16 8 
12 3797 37 22 10 
13 8539 42 23 10 
14 3842 37 22 9 
15 825 45 27 20 
16 6713 23 17 10 
17 6942 44 29 9 
18 2756 46 25 14 
19 5585 38 21 9 
20 7293 35 19 11 
21 5007 47 22 18 
22 728 41 23 13 
23 4927 33 26 16 
24 6610 36 20 10 
25 8665 37 25 14 
26 8404 42 26 13 
27 5582 42 21 11 
28 320 41 30 26 
29 7497 47 22 10 
30 1397 42 26 17 
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  HAEMOGLOBIN LEVEL  
                                  BEFORE AND AFTER TREATMENT 
 
 
S. 
NO 
OP. NO 
PATIENT’S 
AGE 
HEMOGLOBIN LEVEL IN 
GMS/100ML OF BLOOD 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
1 4819 38 8.1 10.3 
2 684 28 7.9 9.1 
3 8610 48 9.0 10.4 
4 891 37 11.5 12.0 
5 124 23 6.3 7.7 
6 2768 45 9.1 10.0 
7 8802 17 9.8 11.0 
8 5812 28 7.7 9.3 
9 3196 22 8.5 10.1 
10 1004 30 6.8 7.5 
11 3663 44 8.3 9.0 
12 3797 37 7.1 8.5 
13 8539 42 10.2 11.1 
14 3842 37 9.7 10.6 
15 825 45 9.0 10.5 
16 6713 23 10 12.2 
17 6942 44 10.4 12.0 
18 2756 46 8.2 10.0 
19 5585 38 9.6 11.0 
20 7293 35 10 11.8 
21 5007 47 8.0 9.5 
22 728 41 9.0 10.2 
23 4927 33 11.0 11.9 
24 6610 36 11.2 12.1 
25 8665 37 8.3 10.2 
26 8404 42 9.3 11.7 
27 5582 42 10.5 12.0 
28 320 41 7.0 9.9 
29 7497 47 9.2 10.5 
30 1397 42 8.0 9.3 
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BLEEDING TIME AND CLOTTING TIME OF PATIENTS 
BEFORE AND AFTER TRETAMENT 
 
S. 
NO 
OP. NO AGE BLEEDING TIME 
Min’Sec’’ 
CLOTTING TIME 
Min’Sec’’ 
BT AT BT AT 
1 4819 38 3’09’’ 2’10’’ 5’48’’ 4’25’’ 
2 684 28 2’40’’ 1’12’’ 5’28’’ 5’10’’ 
3 8610 48 2’10’’ 2’02’’ 4’22’’ 3’56’’ 
4 891 37 2’36’’ 1’10’’ 4’52’’ 5’25’’ 
5 124 23 3’21’’ 2’42’’ 4’46’’ 4’16’’ 
6 2768 45 2’15’’ 1’59’’ 4’11’’ 3’59’’ 
7 8802 17 2’28’’ 2’09’’ 5’42’’ 4’30’’ 
8 5812 28 3’36’’ 2’06’’ 3’24’’ 3’20’’ 
9 3196 22 2’55’’ 2’02’’ 6’10’’ 5’39’’ 
10 1004 30 1’48’’ 1’12’’ 5’22’’ 5’10’’ 
11 3663 44 4’29’’ 3’10’’ 6’44’’ 5’27’’ 
12 3797 37 2’02’’ 1’58’’ 6’42’’ 6’12’’ 
13 8539 42 2’54’’ 1’45’’ 4’48’’ 4’20’’ 
14 3842 37 2’10’’ 2’09’’ 3’48’’ 3’15’’ 
15 825 45 2’18’’ 1’59’’ 4’49’’ 4’25’’ 
16 6713 23 2’32’’ 2’06’’ 5’27’’ 5’10’’ 
17 6942 44 2’51’’ 1’46’’ 4’49’’ 4’20’’ 
18 2756 46 1’28’’ 1’10’’ 4’14’’ 3’59’’ 
19 5585 38 3’14’’ 2’58’’ 5’40’’ 4’16’’ 
20 7293 35 2’11’’ 1’44’’ 5’08’’ 4’30’’ 
21 5007 47 1’48’’ 1’18’’ 5’22’’ 5’32’’ 
22 728 41 3’08’’ 2’05’’ 5’47’’ 5’16’’ 
23 4927 33 3’27’’ 2’44’’ 6’02’’ 6’41’’ 
24 6610 36 2’42’’ 2’15’’ 5’38’’ 5’51’’ 
25 8665 37 3’26’’ 2’10’’ 4’21’’ 4’20’’ 
26 8404 42 1’23’’ 1’06’’ 3’28’’ 3’25’’ 
27 5582 42 2’10’’ 2’11’’ 5’44’’ 5’15’’ 
28 320 41 4’42’’ 3’10’’ 5’40’’ 4’59’’ 
29 7497 47 2’15’’ 1’27’’ 4’35’’ 4’30’’ 
30 1397 42 3’11 2’52’’ 4’18’’ 4’21’’ 
                                                                           RESULTS AND OBSERVATION 
 
An open non-randomized clinical trial of Maampisin Chooranam in Pitha Perumbadu Page 83 
 
                                                                         LAB INVESTIGATION REPORT OF PATIENTS                                        
S 
NO 
OP 
NO BEFORE TREATMENT AFTER TREATMENT BEFORE TREATMENT AFTER TREATMENT 
 
 
 
 
TC DC ESR TC DC ESR SUGAR UREA CHOL SUGAR UREA CHOL 
 
P L E ½ 1 
 
P L E ½ 1 (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) 
1 4819 8100 52 42 6 8 16 8300 50 45 5 3 9 94 32 171 96 31 175 
2 684 7800 64 32 4 18 26 7800 61 34 5 10 20 86 31 174 88 30 180 
3 8610 9100 47 46 7 12 22 9500 46 48 6 3 10 92 38 196 100 36 199 
4 891 9600 62 35 3 14 30 9950 63 34 3 1 2 74 29 160 72 28 158 
5 124 7000 61 35 4 20 40 7400 66 30 4 18 38 78 29 166 85 29 160 
6 2768 8700 52 42 6 7 11 9000 50 45 5 4 11 86 30 140 93 32 149 
7 8802 8600 46 47 7 9 11 9200 51 45 4 2 5 81 30 160 85 29 158 
8 5812 9150 46 50 4 20 42 9300 44 52 4 10 22 82 34 144 90 35 152 
9 3916 7700 54 43 3 8 18 8200 57 40 3 4 8 104 33 150 102 31 145 
10 1004 9000 56 39 5 26 50 9250 59 37 4 14 29 112 30 185 110 34 188 
11 3663 8200 51 41 8 6 13 8800 53 43 4 8 17 78 27 169 81 29 165 
12 3797 9600 57 39 4 25 50 9600 69 29 2 8 19 73 36 180 80 38 181 
13 8539 8300 49 46 5 10 20 9650 48 47 5 2 5 81 38 180 95 40 178 
14 3842 8500 61 31 8 14 28 8600 65 34 1 3 11 108 35 171 104 32 170 
15 825 6100 53 40 7 12 23 7350 58 38 4 4 8 94 27 193 101 29 191 
            TC: TOTAL COUNT          DC: DIFFERENTIAL COUNT                         ESR: ERYTHROCYTE SEDIMENTATION RATE 
             CHOL : CHOLESTROL          
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TC:        TOTAL COUNT                  DC: DIFFERENTIAL COUNT         ESR: ERYTHROCYTE SEDIMENTATION RATE 
           CHOL : CHOLESTROL                                                                                                                                                                                                                                                                          
S 
NO 
OP 
NO BEFORE TREATMENT AFTER TREATMENT BEFORE TREATMENT AFTER TREATMENT 
 
 
 
 
TC DC ESR TC DC ESR SUGAR UREA CHOL SUGAR UREA CHOL 
 
P L E ½ 1 
 
P L E ½ 1 (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) 
16 6713 9400 60 34 6 10 20 9800 64 33 3 1 2 81 38 180 92 37 176 
17 6942 8200 57 39 4 12 25 8300 59 38 3 1 3 99 32 162 97 35 165 
18 2756 9400 62 35 3 9 20 9900 63 36 1 4 9 82 29 173 91 28 179 
19 5585 8800 61 33 6 15 32 9100 60 36 4 2 6 89 30 148 111 27 155 
20 7293 7200 48 47 5 12 27 7550 56 41 3 1 4 92 29 144 96 30 150 
21 5007 8900 60 37 3 10 20 9100 65 32 3 9 17 110 27 178 115 29 172 
22 728 9150 59 36 5 8 17 9300 55 41 4 4 8 99 31 143 90 34 150 
23 4927 9000 53 43 4 2 5 9650 58 41 1 1 2 70 34 151 83 30 147 
24 6610 9700 53 44 3 7 36 9700 50 48 2 1 2 101 36 171 109 34 172 
25 8665 8900 50 44 6 8 19 9100 51 43 6 3 8 73 23 155 71 25 152 
26 8404 6000 58 39 3 10 18 6400 56 41 3 2 3 95 28 167 100 29 166 
27 5582 9900 58 36 6 4 9 9700 61 34 5 1 2 88 39 183 82 36 180 
28 320 9000 48 47 5 31 28 9150 60 39 1 5 12 90 34 152 112 35 153 
29 7497 8300 66 27 7 13 55 8700 66 30 4 4 10 118 35 184 99 33 190 
30 1379 7800 57 39 4 20 33 8000 59 38 3 10 20 98 29 172 94 31 170 
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DISCUSSION 
  
                      PERUMBADU ROGAM has been compared with the modern clinical 
entity MENORRHAGIA. Menstrual disorders are the second most common 
gynaecological condition to be referred to hospitals. Among the menstrual disorders 
MENORRHAGIA is the most common gynaecological disorder in the reproductive 
system of women. Around 30% of women reports heavy menstrual bleeding. 
 
 Most common causes of Menorrhagia are Dysfunctional uterine bleeding, 
Fibroid uterus, endometrial polyp, poly cystic ovarian disease, Adenomyosis and 
chronic tubo-ovarian mass. Long duration of menstrual blood flow, passage of blood 
clots, use of increased number of sanitary pads, pallor and low level of haemoglobin 
give an idea about the correct diagnosis and magnitude of menorrhagia. 
 
 Menorrhagia interferes with a Women’s physical, emotional, social and 
mental quality of life. It can occur alone or in combination with other symptoms. It is 
related to increased limitations in physical activities and limitations in social and 
leisure activities. 
 
 The definitive treatment is appropriate to the cause for Menorrhagia. Hence 
with the help of the trial medicine from the Siddha System of medicine, results and 
observations are noted for this study. 
 
 30 patients with Menorrhagia were selected. The patients were examined 
based on Siddha and as well as modern aspects. All the necessary investigations were 
made for all patients during the study. All the patients were administrated with the 
trial medicine. 
 
 The clinical improvements of the patients were completely observed and 
efficacy of the trial medicine has been studied. Results obtained were discussed below 
for better conclusion. 
Trial drug administered was Maampisin Chooranam – 2 gm thrice a day after 
food for 15 days for 3 consecutive cycles. 
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DRUG AUTHENTICATION  
The required raw drugs were obtained from a well reputed indigenous raw 
drug shop. The raw drugs taken for study were authenticated by the botanist, Siddha 
Central Research Institute, Chennai. 
 
PRE CLINICAL STUDIES 
PHYSIOCHEMICAL ANALYSIS  
The Loss on drying (at 105° C) was 6.67 %  
The total ash value was 3.26 %  
The water soluble ash value was 1.92 %  
The acid insoluble ash value was less than 1 %  
Water soluble extractive value was 36.65 %  
Alcohol soluble extractive value was 21.72 %  
 
TOXICOLOGICAL STUDY  
ACUTE TOXICITY STUDY 
Acute toxicity study of the trial medicine Maampisin Chooranam was carried 
out as per OECD guideline (Organization for Economic Co-operation and 
Development) Guideline-423. The experimental protocol was approved by The 
Institutional Animal Ethics Committee of C.L.Baid Metha College of Pharmacy, 
Chennai, Tamil Nadu, India. IAEC reference number : LI/15/CLBMCP/2017. The 
study was conducted with single oral dose administration of Maampisin Chooranam.  
In acute toxicity test the Maampisin Chooranam was found to be non-toxic at the dose 
level of 2000mg/kg body weight 
.  
SUB-ACUTE TOXICITY STUDY   
Sub-acute toxicity study was carried out for 28 days as per OECD guidelines – 
407. The animals were randomly divided into control group and drug treated groups 
for low and high doses.  At the end of the studies the animals were sacrificed and the 
haematological parameters, biochemical parameters, urine parameters and the 
histopathology of the vital organs like brain, heart, liver, lung and kidney were carried 
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out. The study results show that the trial medicine was safe, and did not produced any 
toxic effects.  
 
PHARMACOLOGICAL EVALUATION  
The experimental protocol was approved by The Institutional Animal Ethics 
Committee of C.L.Baid Metha College of Pharmacy, Chennai, Tamil Nadu, India. 
IAEC: LI/15/CLBMCP/2017. Pharmacological Evaluation of styptic activity of 
Maampisin Chooranam on Adrenochrome induced bleeding time prolongation in rats. 
The result shows that the trial medicine Maampisin Chooranam has styptic activity.  
 
BIOCHEMICAL ANALYSIS   
In Maampisin Chooranam, basic radicals like iron, Phosphate and reducing 
sugar were present. 
  
CLINICAL STUDIES  
STUDY DESIGN  
A clinical trial on PITHA PERUMBADU ROGAM was conducted at the OPD 
section of POST GRADUATE, POTHU MARUTHUVAM DEPARTMENT attached 
to ARIGNAR ANNA GOVERNMENT  HOSPITAL OF INDIAN MEDICINE, 
Chennai-106, during the period 2016-2018.  
 
IEC AND CTRI APPROVAL 
The study was approved by Institutional Ethics Committee (IEC) and the 
approved number is GSMC-CH-ME-5/003/2016. The study was registered in Clinical 
Trials Registry – India (CTRI) and the CTRI number is CTRI/2018/03/012381.    
 
SAMPLE SIZE  
  30 patients  
 
AGE DISTRIBUTION 
Women with the reproductive age 15-50 were affected with the disease. 40% 
of Patients in the age group of 36-45 years were mostly affected, 37% of patients were 
in the age group of 46-50 years. 13% of patients were in the age group of 15-25, 10% 
of patients were in the age group of 26-35 Years. 
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High incidences of cases were noted in age ranging of 36-45 years during the 
studies.  The disease is more common in perimenopausal stage which is usually 
begins in the age of 40 years. 
  
OCCUPATIONAL STATUS  
  63% of patients were house wife, 30% of patients were working women and 
7% of patients were students.  
 
SOCIO-ECONOMIC STATUS  
43% of patients were from lower income group, 40% of patients were middle 
income group and 17% of patients were from lower income group. Heavy menstrual 
bleeding is mainly concerned with low progesterone level and it is generally common 
in women from low income group who are mostly anaemic due to decreased intake of 
healthy foods.   
  
FOOD HABITS  
57% of patients had vegetarian diet and 43% of patients had mixed diet habit. 
Non-vegetarian diet helps in maintaining fairly consistent levels of progesterone 
which results in regular menstrual cycles whereas vegetarian diet leads to 
considerable reductions in progesterone. 
  
DISTRIBUTION OF LANDSCAPES (THINAI)  
 As the trial was conducted in Chennai which is Neithal nilam, most of 
patients about 97% were from Neithal Nilam and 3% of patients were from Marutha 
Nilam.  
Neithal nilam is more prone to Pitha disease. Perumbadu Rogam is mostly 
caused by the derangement of Pitha Kuttram. 
 
SEASONAL REFERENCE  
60% of patients were reported in Pinpani kaalam and 40% of patients were 
reported in  Munpani kaalam.    
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OBSERVATION OF ALTERED MUKKUTRAM  
In Perumbadu, the clinical condition is due to the imbalance of PITHAM. 
Pitham is deranged primarily and later it deranges Vatha and the derangement of 
Pitha-vatha leads to the derangement of Abanaan which in turn cause the disease. The 
pathogenesis of the disease depends upon the affected Pitha and Vatha.  
 
VATHAM  
Abaanan (100%), Pranan (20%),Udhanan (10%), Viyanan (100%), Koorman 
(7%), Samanan (40%), and Devathathan (100)% were affected.  
 Affected Abaanan results in causing excessive and prolonged menstruation 
bleeding.  
 Affected Pranan results in causing dyspnoea and breathlessness due to low Hb 
level.  
 Affected Viyanan results in causing lower abdominal pain and low back ache 
headache and body pain.  
 Affected Udhanan results in producing  nausea, vomiting and cough.  
 Affected Koorman results in causing visual disturbances..  
 Affected Samaanan and Devathathan results in producing loss of appetite or 
indigestion and tiredness respectively. 
  
PITHAM  
Saathagam (100%), Ranjagam (100%), Alosagam (7%), Praasagam (90%) and 
Analagam (97%) were affected.   
 Affected Saathaga  Pitham results in causing general malaise, tiredness and 
giddiness.  
 Affected Ranjaga pitham results in low Hb level.  
 Affected Praasagam results in pallor of skin  due to very low level of 
haemoglobin.   
 Affected Aalosaga pitham results in producing dimness of vision.  
 Affected Analaga Pitham results in causing loss of appetite or indigestion.  
 
KABHAM  
    Kilethagam ( 40%), Tharpagam (10%), Santhigam (67%) were affected. .  
 Affected Santhigam results in producing low back ache.  
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 Affected Kilethagam results in causing loss of appetite.  
 Affected Tharpagam results in producing burning sensation.  
 
EZHU UDAL THATHUKKAL   
Saaram (100%), Senneer (100%), Enbu(67%), Suronitham (100%) were affected.  
 Affected Saaram results in causing loss of appetite and tiredness.  
 Affected Senneer results in causing decreased level of haemoglobin in blood.  
 Affected Enbu results in causing Low back ache.  
 Affected Suronitham results due to presence of excessive menstruation.  
  
ENVAGAI THERVUGAL   
Among 30 patients, Naa (90%), Niram (50%), Vizhi (97%), Malam (20%), 
Moothiram (10%) and Naadi (100%) were affected. Pitha vatha naadi (63%) and  
Vatha pitha naadi (37%).  
 Affected Naa results in pallor of tongue.  
 Affected Niram results in  pallor of the skin due to low Hb level.  
 Affected Vizhi results in paleness of lower eyelids due to low level of 
haemoglobin.  
 Affected Malam was due to constipation.  
 Affected Moothiram was due to burning micturation.   
 
NAADI  
Pitha vatha naadi (65%) and Vatha Pitha naadi (35%) were noticed.   
As per Siddha classical literature, Perumbadu Rogam occurs due to 
derangement of Pitha Naadi and Vatha naadi.  
 
NEIKURI  
Pitha neer (77%) and vatha neer (23%) was observed.  
Perumbadu is a Pitha reflected disease, so most of the patients had Pith neer.  
 
HAEMATOLOGICAL FINDINGS  
              Blood routines were sampled. It was observed that 100% of patients show 
elevation of haemoglobin level in blood. Bleeding time and clotting time investigation 
was taken for affordable patients to exclude blood disorders.  
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SPECIAL INVESTIGATION  
                 USG Abdomen and pelvis was taken before the treatment. The impression 
found on USG pelvis was Fibroid uterus, poly cystic ovarian disease and bulky uterus 
in most of the cases. After confirming the results, the patients were given the trial 
medicine Maampisin chooranam and instructed to follow the diet and other restriction 
based on Siddha System.  
 
MODE OF ACTION OF THE DRUG MAAMPISIN CHOORANAM   
BASED ON TASTE (SUVAI)  
                      In the trial medicine Maampisin Chooranam - most of the ingredients 
included in this trial medicine were thuvarppu and inippu suvai. Basically astringent 
taste has the characteristic action of:  
 Treats the derangement of pitham  
 Causes vaso constriction  
 Decreases the secretions  
 Purifies the blood  
 Cures the ulcer  Basically bitter taste has the following characteristics:  
 Treats the derangement of Pitham.  
 Cures loss of appetite.  
 Removes toxins from body.  
 
Basically sweetness taste has the following characteristics:  
 Treats the derangement of Pitham.  
 Nourishes the body 
 By this, the trial medicine Maampisin Chooranam treats the derangement of 
pitha which is the main cause of disease and also controls bleeding by vaso 
constriction. Hence it acts as an effective drug in Pitha Perumbadu Rogam and 
considered to be Ethirurai maruthuvam.  
 
BASED ON NATURE (VEERIYAM) 
 The trial medicine Maampisin Chooranam is of Thatpam nature as the 
ingredients in this is coolant in nature.  
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CLINICAL MANIFESTATION  
Clinical symptoms before and after treatment were noted. All the patients were 
given score based on Pictorial Blood Loss Assessment Chart (PBAC). The before and 
after treatment score range is taken as improvement.    
Thus the clinical trial study showed significant clinical improvements in 
certain clinical manifestations of Pitha Perumbadu Rogam. Numbers of pads and 
Number of days of menstrual cycle in the patients who had prolonged menstruation 
were decreased due to reduction of increased menstrual blood flow.  
Haemoglobin level of blood is elevated in all the patients. Since, the 
ingredients present in the trial medicine have haematinic activity.  
 
BIO STATISTICAL ANALYSIS 
 Statistical analysis of clinical study before and after treatment was done for 
subjective and objective parameters ( no of pads, menstrual blood loss assessment 
score, bleeding time, clotting time, haemoglobin level). Since the p value (< .0001) is 
highly significant it can be concluded that the treatment for Pitha Perumbadu shows 
improvement in HB level among the patients and reduction in number of pads, 
menstrual blood flow, bleeding time, clotting time. 
  
GRADING OF RESULTS   
Out of 30 patients, 21 cases (70%) shows good result, 6 cases (20%) shows 
moderate result and 3 cases (10%) shows mild result. 
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SUMMARY 
  The clinical study on PITHA PERUMBADU ROGAM was carried out in Post 
graduate department of Maruthuvam, Government Siddha Medical College, Arignar 
Anna Government Hospital, Chennai - 106 during the period of 2016 - 2018.   
A total of 30 patients were treated in the Outpatient department. The clinical 
and pathological assessment was carried out on the basis of Siddha and Modern 
aspects.  All the patients were treated with MAAMPISIN CHOORANAM (2 gm tds). 
The duration of the treatment was fixed as 1 to 15 Days of menstruation for 3 
consecutive cycles. 
 The comparatively larger incidence of Pitha Perumbadu was found to be in 36-
45 years of age. 
 The prevalence of the disease was high among low class populations 43% 
followed by Middle class 40% and Lower class population 17%. 
 Out of 30 patients, 2 patients (7%) were student, 9 patients (30%) were Office 
going people, 19 patients (63%) were house wife. 
 Among dietary patterns, 17 patients (57%) consume vegetarian diet. 
 From selected 30 patients, 12 patients (40%) come under Munpani kaalam and 
18 patients (60%) come under Pinpani Kaalam. 
 Out of 30 patients, 97% comes under Neithal category. 
 In Mukkutram aspect - In Vatham 
Abanan (100%), Pranan (20%), Viyanan (100%), Koorman (7%), Samanan 
(40%) and  Devathathan (100)% were affected. 
 In pitham 
Sathagam (100%), Ranjagam (100%), Alosagam (7%), Praasagam (90%) and 
Analagam (40%) were affected. 
 In Kapham 
Kilethagam (40%), Tharpagam (10%), Santhigam (67%) were affected. 
 Among Ezhu Udal Thathukkal, Saaram (100%), Senneer (100%), Enbu 
(67%), Suronitham (100%) were affected. 
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 Among Envagai Thervugal Naa (90%), Niram (50%), Vizhi (97%), Malam 
(20%), Moothiram (3%), Naadi (100%) were affected. 
 Naadi showed Pitha vatha naadi (63%) and Vatha pitha naadi (37%). 
 In Neikuri examination Pitha neer (77%) and vatha neer (23%) were seen. 
 The ingredients of trial medicines were found to have the properties of 
reducing the symptoms of PITHA PERUMBADU ROGAM. In Maampisin 
Chooranam, basic radicals like phosphate, iron and reducing sugar were 
present.  
 The Toxicological studies of the trial medicine reveal no toxicity. 
 The Pharmacological studies of the trial medicine shows styptic activity. 
 The Bio statistical report of the clinical trial shows significant P value <0.001 
and concluded that, the treatment is effective and significant. 
 Among 30 patients, 70% of cases showed good result and 20% of cases 
showed moderate result and 10% of cases showed mild result in PITHA 
PERUMBADU ROGAM (MENORRHAGIA).  
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CONCLUSION 
 Pitha Perumbadu is primarily due to the derangement of Pitha kuttram.  
 The trial medicine Maampisin Chooranam predominating with Thuvarppu 
suvai, it neutralizes the deranged pitham by Ethirurai Maruthuvam 
 From the preclinical toxicity studies, the medicine Maampisin Chooranam 
revealed no toxicity and proved to be safe.  
  From the preclinical pharmacological studies, it is evident that the medicine 
Maampisin Chooranam has Styptic activity.  
  No adverse effects were reported during the course of the treatment.  
  The medicine Maampisin Chooranam which gives a maximum relief in 
symptoms of Menorrhagia.  
 The ingredients of the trial medicine are easily available.  
  The trial medicine is economical.  
 
Therefore I conclude that, the medicine Maampisin Chooranam can 
give a better solution for Pitha Perumbadu. 
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ACUTE ORAL TOXICITY STUDY OF MAAMPISIN CHOORANAM 
(OECD GUIDELINE – 423) 
 
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals 
of a single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on 
average 2-4 steps may be necessary to allow judgment on the acute toxicity of 
the test substance.  
 This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed 
doses, adequately separated to enable a substance to be ranked for 
classification purposes and hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
 The method allows for the determination of an LD50 value only when at least 
two doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with 
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency 
and repeatability.  
 
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of 
a minimum number of animals per step, sufficient information is obtained on the 
acute toxicity of the test substance to enable its classification. The substance is 
administered orally to a group of experimental animals at one of the defined doses.  
The substance is tested using a stepwise procedure, each step using three 
animals of a single sex. Absence or presence of compound-related mortality of the 
animals dosed at one step will determine the next step, i.e. 
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 no further testing is needed 
 dosing of three additional animals, with the same dose  
 dosing of three additional animals at the next higher or the next lower 
dose level. The method will enable a judgment with respect to 
classifying the test substance to one of a series of toxicity classes. 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wistar albino rat, although other rodent 
species may be used. Healthy young adult animals are commonly used laboratory 
strains should be employed. Females should be nulliparous and non-pregnant. Each 
animal, at the commencement of its dosing, should be between 6 to 8 weeks old and 
the weight (150-200gm) should fall in an interval within±20 % of the mean weight of 
any previously dosed animals. 
  
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals 
may be group-caged by dose, but the number of animals per cage must not interfere 
with clear observations of each animal. 
 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization 
to the laboratory conditions. 
Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
Kings institute, Chennai. All the animals were kept under standard environmental 
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condition (22±3°C).  The animals had free access to water and standard pellet diet 
(Sai meera foods, Bangalore). 
 
Preparation of animals:  The animals are randomly selected, marked to permit 
individual identification, and kept in their cages for at least 7 days prior to dosing to 
allow for acclimatization to the laboratory conditions 
Preparation for Acute Toxicity Studies 
 Rats were deprived of food overnight (but not water 16-18 h) prior to 
administration of the MAAMPISIN CHOORANAM 
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design 
IAEC No: LI/15/CLBMCP/2017 
 
Test Substance  : MAAMPISIN CHOORANAM  
Animal Source  : Kings institute, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : >6 weeks 
Body Weight on Day 0 :180-280 gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual   
       marking by using Picric acid. 
Number of animals  : 3 Female/group,  
Route of administration :   Oral  
 
Diet    : Pellet feed supplied by Sai meera foods Pvt 
Ltd,Bangalore 
Water    : Aqua guard portable water in polypropylene bottles 
. 
Housing & Environment : The animals were housed in Polypropylene cages  
        provided with bedding of husk. 
Housing temperature : between 22ºC + 3ºC.  
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Relative humidity  : between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
Administration of Doses:  
 MAAMPISIN CHOORANAM was suspended in water and administered to 
the groups of wistar albino rats in a single oral dose by gavage using a feeding needle. 
The control group received an equal volume of the vehicle. Animals were fasted 12 
hours prior to dosing. Following the period of fasting, the animals were weighed and 
then the test substance was administered. Three Female animals are used for each 
group. The dose level of 3, 30, 300 and 2000 mg/kg body weight was administered 
stepwise. After the substance has been administered, food was withheld for a further 
3-4 hours. The principle of laboratory animal care was followed. Observations were 
made and recorded systematically and continuously as per the guideline after 
substance administration. The visual observations included skin changes, mobility, 
aggressively, sensitivity to sound and pain, as well as respiratory movements. Finally, 
the number of survivors was noted after 24 hours and these animals were then 
monitored for a further 14 days and observations made daily. The toxicological effect 
was assessed on the basis of mortality. 
 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. 
 
Observations include changes in skin and fur, eyes and mucous membranes, 
and also respiratory, circulatory, autonomic and central nervous systems, and 
somatomotor activity and behavior pattern. Attention was directed to observations of 
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tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles 
and criteria summarized in the Humane Endpoints Guidance Document taken into 
consideration. Animals found in a moribund condition and animals showing severe 
pain or enduring signs of severe distress was humanly killed. When animals are killed 
for human reasons or found dead, the time of death was recorded. 
 
Acute oral toxicity study of MAAMPISIN CHOORANAM 
 
Table 1: Dose finding experiment and its behavioral signs of acute oral Toxicity 
 
Observation done: 
SL 
Group 
CONTROL 
Observation SL 
Group 
TEST GROUP 
Observation 
1 Body weight Normal 1 Body weight Normally increased 
 2 Assessments of posture Normal 2 Assessments of 
posture 
Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal 3 Signs of 
Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
6 Salivation Normal 6 Salivation Absence 
7 Change in skin color 
No significant 
color change 
7 
Change in skin 
color 
No significant 
color change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation Normal 
 
9 Defecation Normal 
 10 Sensitivity response Normal 10 Sensitivity 
response 
Normal 
11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 Muscle gripness Normal 
13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
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Behavior: 
 The animals will be observed closely for behavior in the first four hours which  
includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, catalepsy, 
convulsion, excitation, head twitches, lacrimation, loss of corneal reflex, loss of 
traction, piloerection  reactivity of touch, salivation, scratching, sedation, chewing,  
head movements, sniffing, straub, tremor and writhes, diarrhea, leathery, sleep and 
coma. 
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight 
changes were calculated and recorded. At the end of the test, surviving animals were 
weighed and humanly killed. 
 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated dose 
groups.  
 
Mortality: 
Animals were observed for mortality throughout the entire period. 
 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test 
group the number of animals used, the number of animals displaying signs of toxicity, 
the number of animals found dead during the test, description of toxic symptoms, 
weight changes, food and water intake. 
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No of animals in each group:3 
Table 2 (Observational study Results) 
 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
 
2000 
mg/kg 
 
+ - - + - + - - - - - - - - - - - - - - 
 
1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. 
Exophthalmos 17. Diarrhea 18. Writhing  
19. Respiration 20. Mortality. 
(+  Present, -  Absent) 
 
Table 3( Body weight Observation) 
 
 
 
 
 
 
 
 
 
 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 
166.6± 
1.95 
168.2± 4.82 169.2 ± 3.12 
2000 mg/kg 
172.3± 
2.18 
174.2± 1.26 177.2 ± 3.27 
P value (p)* NS NS NS 
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Table 4 (Water intake (ml/day) of Wistar albino rats group exposed to 
(MAAMPISIN CHOORANAM): 
 
 
N.S- Not Significant,**(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Table 5: Food intake (gm/day) of Wistar albino rats group exposed to 
MAAMPISIN CHOORANAM 
DOSE 
 
DAYS 
1 7 14 
CONTROL 25.16±6.36 27.60±3.12 27.61±5.46 
2000 mg/kg 27.42±1.64 28.31±3.22 28.12±6.14 
P value (p)* NS NS NS 
 
 
REPEATED DOSE 28-DAY ORAL TOXICITY STUDY OF MAAMPISIN 
CHOORANAM 
Test Substance  : MAAMPISIN CHOORANAM  
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : >6 weeks 
Body Weight    :160-180 gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
DOSE 
 
DAYS 
1 6 14 
CONTROL 32.5 ± 1.34 33.0± 10.13 32.4± 3.13 
2000 mg/kg 29.4±2.33 30.6±1.91 30.9± 2.19 
P value (p)* NS NS NS 
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Identification of animals : By cage number, animal number   and    individual  
 marking by using    Picric acid 
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd,       
      Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
      provided with bedding of husk. 
Housing temperature : between 22ºC + 3ºC.  
Relative humidity  : between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
 
Table 5  
 
Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. 
Each group consist of 12 animals (Male -6, and Female-6). First group treated as a 
control and other three group were treated with test drug (low, mid, high) for 28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior 
to the initiation of treatment. Each animal was marked with picric acid. The females 
were nulliparous and non-pregnant. 
 
 
 
                                        Groups No of Rats 
Group I  - Control Vehicle control (Normal Saline ) 12(6male,6 female) 
Group II -  Low Dose Maampisin Chooranam 20 Mg/Kg 12 (6male,6 female) 
Group III  - Mid Dose Maampisin Chooranam 100 Mg/Kg 12 (6male,6female) 
Group IV – High Dose Maampisin Chooranam 200 Mg/Kg 12(6male,6female) 
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Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are 
low dose (20 mg/kg), mid dose dose (100 mg/kg), high dose (200 mg/kg). X is 
calculated by multiplying the dose (2000mg/kg) i.e X dose is 20 mg/kg/animal 
,5Xmid dose is 100 mg/kg, 10X high dose is 200 mg/kg. 
 
Preparation and Administration of Dose: 
 MAAMPISIN CHOORANAM is suspended in water, It was administered to 
animals at the dose levels of 20, 100 and 200 mg/kg. The test substance suspensions 
were freshly prepared every two days once for 28 days. The control animals were 
administered vehicle only. The drug was administered orally by using oral gavage 
once daily for 28 consecutive days. 
 
Observations: 
Experimental animals were kept under observation throughout the course of 
study for the following: 
 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course 
of study. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the 
treated dose groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
Mortality: 
All animals were observed twice daily for mortality during entire course of  
study. 
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Necropsy: 
All the animals were sacrificed by excessive anaesthesia on day 29. Necropsy 
of all animals was carried out. 
 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals 
fasted over-night. Blood samples were collected from orbital sinus using sodium 
heparin (200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for 
Hematology as anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 
minutes. 
 
Haematological Investigations: 
Haematological parameters were determined using Haematology analyzer.  
Biochemical Investigations:  
Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group 
than the low, then the mid dose group will also be examined. Organs will be collected 
from all animals and preserved in 10% buffered neutral formalin for 24 h and washed 
in running water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in 
an auto technicon and then cleared in benzene to remove absolute alcohol. Embedding 
was done by passing the cleared samples through three cups containing molten 
paraffin at 50°C and then in a cubical block of paraffin made by the “L” moulds. It 
was followed by microtome and the slides were stained with Haematoxylin-eosin red. 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, 
hematology and blood chemistry were subjected to One-way ANOVA followed by 
dunnett test using a computer software programme – Graph pad  version 5.0 .All data 
were summarized in tabular form, (Table-6 to 12) 
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RESULTS 
Repeated Dose 28- day oral toxic study of MAAMPISIN CHOORANAM  
Table 6: Body weight of wistar albino rats group exposed to MAAMPISIN 
CHOORANAM 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
Table 7: Water intake (ml/day) of Wistar albino rats group exposed to 
MAAMPISIN CHOORANAM 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 51.5 ± 
7.15 
50.0 ± 8.23 58.5± 6.63 49.12±7.19 51.5±3.96 
LOW 
DOSE 
38.5±3.41 39.4±3.62 39.27±4.12 38.2±3.29 39.9±3.13 
MID DOSE 36.7±4.13 36.3±2.21 37.1±4.13 38.4±6.31 38.4±3.34 
HIGH 
DOSE 
32.1±1.32 33.2±4.13 34.7±3.13 32.2±1.73 30.4±2.65 
P value 
(p)* 
NS NS NS NS NS 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 
172.0±  
4.23 
172.4 ± 
3.42 
174.7 ± 1.36 
174.2 ± 
1.33 
175.7 ± 
1.31 
LOW DOSE 
171.2 ± 
3.12 
172.7 ± 
4.64 
175.4± 3.18 
175.8 ± 
1.86 
176.12± 
2.36 
MID DOSE 178.6± 1.34 
179.3 ± 
2.14 
180.4 ± 6.32 
182.1 ± 
3.16 
183.7 ± 
3.12 
HIGH 
DOSE 
187.4± 8.14 
189.6 ± 
3.12 
189.6 ± 2.16 
190.0± 
6.21 
191.92 ± 
2.19 
P value (p)* NS NS NS NS NS 
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Table 8:Food intake (gm/day) of Wistar albino rats group exposed to 
MAAMPISIN CHOORANAM 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 29.12 
±5.37 
28.5±4.22 29.5±4.27 32.5±3.87 33.12±6.32 
LOW 
DOSE 
33.7±4.98 34.3±1.22 33.1±6.18 35.4±6.12 35.6±2.12 
MID DOSE 32.2±4.75 33.2±6.80 37.2±1.25 33.4±2.68 32.2±1.44 
HIGH 
DOSE 
32.2±2.34 32.2±2.64 34.6±2.16 36.2±3.14 37.0±1.62 
P value 
(p)* 
NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test. 
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Table 9: Haematological parameters of Wistar albino rats group exposed to 
MAAMPISIN CHOORANAM   
 
Category Control Low dose Mid dose High dose P 
value 
(p)* 
Haemoglobin(
g/dl) 
14.8±1.88 13.1±3.16 13.64±3.6
6 
14.28±0.9
6 
N.S 
Total WBC 
(×10
3   
l) 
10.91±2.59 10.25±6.7
3 
11.28±2.3
1 
11.40±6.1
4 
N.S 
Neutrophils(
%) 
32.65±1.06 32.13±4.1
4 
33.11±1.4
6 
34.40±3.2
0 
N.S 
lymphocyte 
(%) 
69.34±2.48 70.16±6.1
2 
71.58±4.6
6 
74.13±4.1
6 
N.S 
Monocyte (%) 0.78±0.17 0.76±0.04 0.80±0.13 0.83±0.36 N.S 
Eosinohil(%) 0.64±0.09 0.64±0.16 0.75±0.43 0.73±0.14 N.S 
Platelets 
cells10
3
/µl 
687.17±8.7
6 
722.71± 
2.16 
705.18± 
2.0 
735.16± 
3.14 
N.S 
Total RBC 
10
6
/µl 
7.99±0.12 6.82±1.37 7.12±1.89 7.18±7.72 N.S 
PCV% 37.79±0.6 41.35±8.1
3 
42.18±1.6
8 
43.82±2.5
4 
N.S 
MCHC g/dL 33.6±2.23 32.19±5.2
9 
33.18±4.2
2 
32.93±1.2
4 
N.S 
5MCV 
fL(µm
3
) 
49.17±3.64 48.29±1.2
2 
50.18±1.2
4 
50.94±1.4
4 
N.S 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
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Table 10 :Biochemical Parameters of Wistar albino rats group exposed to 
MAAMPISIN CHOORANAM 
BIOCHEMICAL 
PARAMETERS 
CONTRO
L 
LOW 
DOSE 
MID 
DOSE 
HIGH 
DOSE 
P 
Value 
(p)* 
GLUCOSE (R) 
(mg/dl) 
76.45±13.4 76.16±2.34 
75.26±2.2
0 
77.42±2.64 N.S 
T.CHOLOSTEROL(
mg/dl) 
115.26±1.8
3 
109.45±4.1
3 
118.42±4.
78 
123.22±3.7
3 
N.S 
TRIGLY(mg/dl) 46.35±1.48 44.22±1.48 
48.58±1.3
0 
47.66±3.33 N.S 
LDL 72.81±2.13 76.24±8.14 74.8±2.14 70.64±4.32 NS 
VLDL 15.2±2.44 14.42±4.64 
14.04±1.6
4 
13.94± 1.46 NS 
HDL 26.66±6.88 23.86±6.24 
26.10±2.6
6 
30.68±1.12 NS 
Ratio 1(T.CHO/HDL) 4.42±2.44 4.46±3.14 4.64±2.14 4.18 ± 2.12 NS 
Ratio 2(LDL/HDL) 
 
2.83±4.22 2.14 ± 2.22 
2.28± 
2.20 
2.16±6.22 NS 
Albumin(g/dL) 
3.63±0.17 3.18±0.42 3.16±2.62 
2.94±4.16 
NS 
  
NS- Not Significant,**(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
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Table 11: Renal function test of of Wistar albino rats group exposed to 
MAAMPISIN CHOORANAM 
 
 
PARAMETERS CONTROL 
LOW 
DOSE 
MID 
DOSE 
HIGH 
DOSE 
P 
Value 
(p)* 
UREA (mg/dl) 13.35±0.99 13.14±0.16 12.96±1.98 12.28±3.62 N.S 
CREATININE 
(mg/dl) 
0.28±0.08 0.36±0.06 0.52±0.04 0.66±0.02 N.S 
BUN (mg/dL) 15.02±0.10 14.28±1.92 14.09±1.34 14.02±4.32 NS 
URIC ACID 
(mg/dl) 
5.17±0.35 5.01±1.03 5.12±3.15 4.58±1.33 NS 
 
 NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
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Table 12: Liver Function Test of  Wistar albino rats group exposed to 
MAAMPISIN CHOORANAM 
 
 
PARAMETERS 
CONTRO
L 
LOW 
DOSE 
MID 
DOSE 
HIGH 
DOSE 
P 
Valu
e 
(p)*  
T 
BILIRUBIN(mg/dl
). 
0.48±0.07 0.40±1.26 0.41±3.28 0.39±1.25 N.S 
SGOT/AST(U/L) 79.95±1.39 76.15±1.31 77.31±3.03 79.25±4.03 N.S 
SGPT/ALT(U/L) 31.23±1.28 32.91±3.59 36.24±7.48 34.12±1.68 N.S 
ALP(U/L) 
143.25±8.7
0 
146.12±1.3
7 
143.16±4.1
7 
145.33±1.6
5 
NS 
T.PROTEIN(g/dL) 5.32±0.38 5. 22±1.14 6.01±3.23 6.93±1.46 N.S 
 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
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                     HISTOPATHOLOGY OF VITAL ORGANS  
              Low dose                                               High dose  
 
BRAIN  
                                            
             Cerebellum – Normal                                        Cerebellum – Mild gliosis                                                                               
     
 HEART  
                                                
 Normal Cardiomyocytes                              Normal Cardiomyocytes 
KIDNEY 
         
Cortex – Normocellular glomeruli                     Cortex – Normocellular glomeruli 
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LIVER   
                              
        Normal                                        Periportal zone – Normal 
LUNG 
                                         
                     Normal                                                                   Normal  
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HISTOPATHOLOGY REPORT 
BRAIN   
Arrangement of the neurons appears intact with no signs of degeneration was 
observed in sample.  
HEART   
Myocardial fiber mass appears denser with no signs of degeneration or fibrosis were 
observed in samples. 
LIVER   
Appearance of portal triad was normal with no signs of inflammatory cell infiltration. 
Liver parenchyma appears normal. No evidence of necrosis were observed in 
samples.  
KIDNEY   
Appearance of proximal and distal convolutes tubules was normal with no evidence of 
atrophy.  
LUNG   
Microscopic examination of lung revealed normal alveoli and alveolar sac with no 
signs of infiltration.   
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AN EVALUATION OF THE SIDDHA DRUG MAAMPISIN 
CHOORANAM FOR ITS STYPTIC ACTIVITY 
IN WISTER ALBINO RATS 
 
ANIMAL PROCUREMENT AND MAINTENANCE 
Wistar Albino rats of either sex, weighing 150 g to 200 g were purchased from 
Kings Institute of Preventive medicine Animal House, Chennai, India. Animal ethical 
guidelines of CPCSEA, Ministry of Animal Husbandry and Welfare, Govt. of India 
were strictly followed for the care and maintenance of procured animals. The animals 
were fed on standard rodent pellet and RO water was provided ad libitum. The 
animals were kept for overnight fasting before experimentation. 
 
DRUG PROFILE 
Adrenochrome is a by- product of oxidized adrenaline. Its chemical name is 3-
hydroxy-1-methyl-5, 6-indoline-dione. Adrenochrome can refer to two things: a 
metabolite of endogenous epinephrine or a product of metabolized pharmaceutical 
epinephrine. This drug is controversial because there are debates as to what class this 
drug belongs to. Adrenochrome is believed to have psychoactive and hallucinogenic 
effects. This means that it is believed to change the user's behavior, perception, mood 
and consciousness and also cause the person to hallucinate. It is believed that 
adrenochrome may produce effects similar to, but milder than LSD and psilocybin. 
 
PROCEDURE  
Animals were randomized into four groups of six animals each.  
1. Group I received vehicle,  
2. Group II received test drug 100mg  
3. Group III received test drug 200mg  
4. Group IV served as standard. (Tranexamic acid-TA) 
 
The animals were administered the test drug orally and the blood sample were 
collected periodically for evaluation. 
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CLOTTING TIME (CT) 
The tail of the animal is warmed for 1 min in water at 40°C, dried and cut at 
the tip with a razor blade. A 25 μl sample of capillary blood was collected into a 
microhematocrit glass capillary. The chronometer was started when the blood is first 
made contact with the glass capillary tube. The blood left to flow by gravity between 
the two marks of the tube, 45 mm apart, by tilting the capillary tube alternately to 
+60° and -60° angles with respect to the horizontal plane until blood ceased to flow 
(reaction end point).  
 
BLEEDING TIME (BT) 
The tail of the rat is warmed for 1min in water at 40°C and then dried. A small 
cut was made in the middle of the tail with a scalpel. Bleeding time started and noted 
when the first drop touched the circular filter paper and checked at 30 s intervals until 
bleeding stops.  
 
PROTHROMBIN TIME (PT)  
0.1 ml of plasma mixed with 0.2 ml of PT reagent (calcium thromboplastin) 
maintain 37
o
C, and observe the animals until formation of the fibrin clot. The time 
should be noted.  
 
ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)  
0.1 ml of plasma with 0.1mi of APTT reagent (cephalin-karolin suspension) 
incubated 37
o
C for 5 minutes and then adds 0.1ml of 0.025ml cacl2 solution, until 
formation of the fibrin clot visually detected. The time should be noted.  
 
FIBRINOGEN TIME  
0.25ml of animal blood plasma add 0.05 ml of saline, and incubated 37
o
C. 
After 30sec add 0.1ml of streptokinase solution, wait for 30sec, then add 0.1ml of 
bovine thrombin added. Start the stopwatch note at which time the fibrinogen clot 
formed.  
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METHOD: 
 After, one hour of treatment to the above respective groups, the 
following parameters such as BT, CT, Prothrombin time, Activated partial 
Thromboplastin time, Thrombin time and Fibrinogen were screened. 
 
 
RESULTS AND DISCUSSION: 
 
BLOOD STYPTIC PARAMETERS 
 B lo o d  S y s tic  p a r a m e te r s
S y s tic  p a ra m e te rs
S
e
c
B
T
C
T
P
T
A
T
T
F
T
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
G rp  1
G rp  2
G rp  3
G rp  4
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S. 
no 
Groups Bleeding 
time (sec) 
Clotting 
time (sec) 
Prothrombi
n time  
Activated 
Thromboplasti
n time 
Fibrinogen 
time 
1 Control 84.32±2.22 119.4±1.24 26.26±1.44 27.12±5.22 196.4±3.22 
2 Low dose 96.21±4.21 117.2±6.21 25.54±0.43 24.42±6.42 175.2±2.20 
3 High dose 92.52±3.11 108.6±4.44 22.11±1.64 17.12±5.22 145.6±4.32 
4 Standard 81.42±3.64 101.7±6.62 19.2±1.22 13.06±4.11 115.8±5.42 
 
Values are expressed as mean ± S.D followed by Dunnett’s Test. *P < 0.05, **P < 
0.01, ***P<0.001 compared. 
 
Haemorrhage is responsible for 50% deaths occurring within 24 hours of 
traumatic injury. Haemorrhage is also a leading cause of death associated with blood 
transfusion. There is a need for the improvement of current treatments of bleeding 
associated with surgery, trauma or other tissue damages. An ideal styptic with fewer 
side effects and cost effective is the need of the hour. The results of the present 
investigation show that a significant reduction in the bleeding time, clotting time, 
prothrombin time and fibrinogen. These were reduced in a dose dependent manner. 
 
CONCLUSION  
                 By the observed results, the values of trial drug Maampisin Chooranam 
treated animals were compared with the positive control drug Adrenochrome 10 
µg/animal/i.p, single dose. The results (mean value) are assured as a good styptic 
activity response of trial drug.  
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BIO-CHEMICAL ANALYSIS OF TRIAL MEDICINE 
 
Preparation of Sodium Carbonate extract: 
 
2 gm of the sample drug is mixed 5 gm of Sodium carbonate and taken in a 
100 ml beaker and 20 ml of distilled water is added. The solution is boiled for 10 
minutes, cooled and then filtered. The filtrate is called sodium carbonate extract. 
S.No EXPERIMENT OBSERVATION INFERENCE 
I                                    TEST FOR ACID RADICALS 
1a Test for Sulphate 
2 ml of the above prepared extract 
is taken in a test tube. To this add 
2ml of 4% Ammonium oxalate 
solution. 
Absence of 
White Precipitate 
Absent 
b 2ml of extract is added with 2ml 
of dilute hydrochloric acid until 
the effervescence ceases off. Then 
2ml barium chloride solution is 
added. 
Absence of 
White Precipitate 
Absent 
2 Test for Chloride: 
2ml of extract is added with dilute 
nitric acid till the effervescence 
ceases. Then 2ml of silver nitrate 
solution is added. 
Absence of white 
precipitate 
obtained 
Absent 
3 Test for Phosphate 
2ml of the extract is treated 
with 2 ml of Ammonium 
molybdate solution and 2ml of 
concentrated nitric acid. 
 
Yellow precipitate 
obtained 
Present 
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4 Test for Carbonate: 
2ml of the extract is treated 
with 2ml of magnesium 
sulphate solution. 
 
Absence of white 
precipitate 
Absent 
5 Test for Sulphide: 
1 gm of the substance is treated 
with 2ml of concentrated 
Hydrochloric acid 
 Rotten egg smelling Absent 
6 Test for Nitrate: 
1gm of the substance is heated 
with copper turnings and 
concentrated sulphuric acid 
and viewed the test tube 
vertically down. 
Absence of reddish 
brown gas. 
Absent 
 
7a Test for Fluoride and oxalate 
2ml of the extract is added with 
2ml of dilute acetic acid and 
2ml of calcium chloride 
solution and heated. 
 White precipitate Absent 
b 5 drops of clear solution is 
added with 2ml of dilute 
sulphuric acid and slightly 
warmed to this, 1 ml of dilute 
potassium permanganate 
solution is added. 
 
 KMNO4 solution 
Discolourisation 
obtained 
Absent 
8 Test for Nitrite 
3 drops of the extract is placed 
on a filter paper. On that, 2 
drops a Acetic Acid and 2 
drops of Benzidine solution is 
placed. 
Absence of 
yellowish red colour 
Absent 
9 Test for Borate Absence of Green Absent 
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2 pinches of the substance is 
made into paste by using 
Sulphuric acid and Alcohol 
(95%) and introduced into the 
blue flame. 
tinged flame 
II                                     TEST FOR BASIC RADICALS 
10 Test for lead 
2 ml of the extract is added 
with 2 ml of Potassium iodide 
solution. 
Absence of Yellow 
precipitate 
Absent 
11a Test for Copper 
One pinch of substance is 
made into paste with 
concentrated Hydrochloric acid 
in a watch glass and introduced 
into the non luminous part of 
the flame. 
Absence of Bluish 
green coloured 
flame. 
Absent 
b 2ml of the extract is added with 
excess of Ammonia solution 
Absence of deep 
blue 
Absent 
12 Test for Aluminium 
To the 2 ml of extract. Sodium 
Hydroxide solution is added in 
drops to excess. 
 
Absence of White 
Precipitate. 
Absent 
13a Test for Iron 
To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
Solution is added. 
 Blood red colour Present 
b To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution and 2 ml of 
concentrated HNO3 is added. 
Blood red colour 
obtained 
Present 
14 Test for Zinc Absence of White Absent 
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To the 2 ml of extract Sodium 
Hydroxide solution is added in 
drops to excess. 
precipitate. 
15 Test for Calcium 
2 ml of the extract is added 
with 2 ml of 4% Ammonium 
Oxalate solution. 
Absence of White 
precipitate. 
Absent 
16 Test for Magnesium 
2ml of extract, Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of White 
precipitate. 
Absent 
17 Test for Ammonium 
2 ml of extract few ml of 
Nessler’s Reagent and excess 
of Sodium Hydroxide solution 
are added. 
Absence of 
Reddish brown 
precipitate 
Absent 
18 Test for Potassium 
A pinch of substance is treated 
with 2 ml of Sodium Nitrite 
solution and then treated with 2 
ml of Cobal Nitrate in 30% 
glacial Acetic acid. 
Absence of Yellow 
precipitate 
 
Absent 
19 Test for Sodium 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame 
 
Absence of Yellow 
colour flame 
Absent 
20 Test for Mercury 
2 ml of the extract is treated 
with 2 ml of Sodium 
Hydroxide solution. 
Absence of yellow 
precipitate 
Absent 
21 Test for Arsenic 
2 ml of extract is treated with 2 
Absence of 
Yellow precipitate 
Absent 
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ml of silver Nitrate solution 
22 Test for Starch 
2ml of extract is treated with 
weak iodine solution 
Absence of 
Blue colour 
Absent 
23 Test of reducing Sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and added 10 drops of 
the extract and again boiled for 
2 minutes. The colour changes 
are noted. 
  Green colour  Present 
24 Test of the alkaliods 
2ml of the extract is treated 
with 2ml of potassium lodide 
solution. 
 
 
 
Absence of 
Red colour 
Absent 
25 Test of the proteins 
2ml of the extract is treated 
with 2ml of 5% NaOH ,mix 
well and add 2 drops of copper 
sulphate solution. 
Absence of 
Violet colour 
Absent 
 
RESULTS: 
                   The given sample (Maampisin Chooranam) contains  
i) Phosphate  
ii) Iron   
iii) Reducing sugar. 
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BIO STATISTICAL ANALYSIS 
Treatment for Pitha Perumbadu: 
The most popular non parametric statistical tool, namely, McNemar Test 
analysis has been employed to analyses the effectiveness with the help of a 
hypothesis. 
NO. OF PADS 
Software: spss17 version  
Variables: Number of Pads– before treatment, after treatment  
Number of cases: 30  
S. NO OP. NO PATIENT’S 
AGE 
NUMBER OF PADS FOR A CYCLE 
BEFORE TREATMENT AFTER TREATMENT 
1 4819 38 21 9 
2 684 28 32 20 
3 8610 48 26 21 
4 891 37 22 8 
5 124 23 30 10 
6 2768 45 20 9 
7 8802 17 39 21 
8 5812 28 21 13 
9 3196 22 28 16 
10 1004 30 25 14 
11 3663 44 16 8 
12 3797 37 22 10 
13 8539 42 23 10 
14 3842 37 22 9 
15 825 45 27 20 
16 6713 23 17 10 
17 6942 44 29 9 
18 2756 46 25 14 
19 5585 38 21 9 
20 7293 35 19 11 
21 5007 47 22 18 
22 728 41 23 13 
23 4927 33 26 16 
24 6610 36 20 10 
25 8665 37 25 14 
26 8404 42 26 13 
27 5582 42 21 11 
28 320 41 30 26 
29 7497 47 22 10 
30 1397 42 26 17 
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Paired Samples Statistics 
 
 Mean N Std. Deviation Std. Error Mean 
 
PADS_BT 20.1667 30 4.25144 .77620 
PADS_AT 11.6667 30 3.41733 .62392 
 
 
Paired Samples Test 
 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
PADS_BT 
- 
PADS_AT 
8.50000 3.94575 .72039 7.02663 9.97337 11.799 29 .000 
 
 
Inference: 
 Since the P value is highly significant (<0.00), The hypothesis is not 
accepted.  So the treatment was significantly reducing the number of pads used by the 
patients for the treatment of Pitha Perumbadu.  
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HAEMOGLOBIN  LEVEL: 
Software: spss17 version  
Variables: Hb level (gm/dl)– before treatment, after treatment  
Number of cases: 30  
 
S. NO OP. NO 
PATIENT’S 
AGE 
HEMOGLOBIN LEVEL IN 
GMS/100ML OF BLOOD 
BEFORE 
TREATMENT 
AFTER TREATMENT 
1 4819 38 8.1 10.3 
2 684 28 7.9 9.1 
3 8610 48 9.0 10.4 
4 891 37 11.5 12.0 
5 124 23 6.3 7.7 
6 2768 45 9.1 10.0 
7 8802 17 9.8 11.0 
8 5812 28 7.7 9.3 
9 3196 22 8.5 10.1 
10 1004 30 6.8 7.5 
11 3663 44 8.3 9.0 
12 3797 37 7.1 8.5 
13 8539 42 10.2 11.1 
14 3842 37 9.7 10.6 
15 825 45 9.0 10.5 
16 6713 23 10 12.2 
17 6942 44 10.4 12.0 
18 2756 46 8.2 10.0 
19 5585 38 9.6 11.0 
20 7293 35 10 11.8 
21 5007 47 8.0 9.5 
22 728 41 9.0 10.2 
23 4927 33 11.0 11.9 
24 6610 36 11.2 12.1 
25 8665 37 8.3 10.2 
26 8404 42 9.3 11.7 
27 5582 42 10.5 12.0 
28 320 41 7.0 9.9 
29 7497 47 9.2 10.5 
30 1397 42 8.0 9.3 
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Paired Samples Statistics 
 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 
HB_BT 
8.9567 30 1.33434 .24362 
HB_AT 10.3800 30 1.28530 .23466 
 
 
Paired Samples Test 
 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
HB_BT 
- 
HB_AT 
-
1.42333 
.53863 .09834 -
1.62446 
-
1.22220 
-
14.474 
29 .000 
 
Inference:   
Since the P value is highly significant (<0.000), The hypothesis is not 
accepted.  So the treatment was significantly improving the Hb level among the 
patients for the treatment of Pitha Perumbadu.  
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BLEEDING TIME: 
Software: spss17 version  
Variables:bleeding time(min)– before treatment, after treatment  
Number of cases: 30  
S. 
NO 
OP. NO AGE BLEEDING TIME 
Min’Sec’’ 
CLOTTING TIME 
Min’Sec’’ 
BT AT BT AT 
1 4819 38 3’09’’ 2’10’’ 5’48’’ 4’25’’ 
2 684 28 2’40’’ 1’12’’ 5’28’’ 5’10’’ 
3 8610 48 2’10’’ 2’02’’ 4’22’’ 3’56’’ 
4 891 37 2’36’’ 1’10’’ 4’52’’ 5’25’’ 
5 124 23 3’21’’ 2’42’’ 4’46’’ 4’16’’ 
6 2768 45 2’15’’ 1’59’’ 4’11’’ 3’59’’ 
7 8802 17 2’28’’ 2’09’’ 5’42’’ 4’30’’ 
8 5812 28 3’36’’ 2’06’’ 3’24’’ 3’20’’ 
9 3196 22 2’55’’ 2’02’’ 6’10’’ 5’39’’ 
10 1004 30 1’48’’ 1’12’’ 5’22’’ 5’10’’ 
11 3663 44 4’29’’ 3’10’’ 6’44’’ 5’27’’ 
12 3797 37 2’02’’ 1’58’’ 6’42’’ 6’12’’ 
13 8539 42 2’54’’ 1’45’’ 4’48’’ 4’20’’ 
14 3842 37 2’10’’ 2’09’’ 3’48’’ 3’15’’ 
15 825 45 2’18’’ 1’59’’ 4’49’’ 4’25’’ 
16 6713 23 2’32’’ 2’06’’ 5’27’’ 5’10’’ 
17 6942 44 2’51’’ 1’46’’ 4’49’’ 4’20’’ 
18 2756 46 1’28’’ 1’10’’ 4’14’’ 3’59’’ 
19 5585 38 3’14’’ 2’58’’ 5’40’’ 4’16’’ 
20 7293 35 2’11’’ 1’44’’ 5’08’’ 4’30’’ 
21 5007 47 1’48’’ 1’18’’ 5’22’’ 5’32’’ 
22 728 41 3’08’’ 2’05’’ 5’47’’ 5’16’’ 
23 4927 33 3’27’’ 2’44’’ 6’02’’ 6’41’’ 
24 6610 36 2’42’’ 2’15’’ 5’38’’ 5’51’’ 
25 8665 37 3’26’’ 2’10’’ 4’21’’ 4’20’’ 
26 8404 42 1’23’’ 1’06’’ 3’28’’ 3’25’’ 
27 5582 42 2’10’’ 2’11’’ 5’44’’ 5’15’’ 
28 320 41 4’42’’ 3’10’’ 5’40’’ 4’59’’ 
29 7497 47 2’15’’ 1’27’’ 4’35’’ 4’30’’ 
30 1397 42 3’11 2’52’’ 4’18’’ 4’21’’ 
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Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 
BLT_BT 
2.5330 30 .77128 .14082 
BLT_AT 1.8690 30 .57659 .10527 
 
 
Paired Samples Test 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
BLT_BT 
- 
BLT_AT 
.66400 .42843 .07822 .50402 .82398 8.489 29 .000 
 
1. CLOTTING TIME  
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
 
CLT_AT 
4.8897 30 .85205 .15556 
CLT_BT 4.5447 30 .83550 .15254 
 
 
Paired Samples Test 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
CLT_AT 
- 
CLT_BT 
.34500 .46841 .08552 .17009 .51991 4.034 29 .000 
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Inference:   
Since the P value is significant (<0.000), The hypothesis is not accepted.  So the 
treatment was significantly reducing the bleeding time among the patients for the 
treatment of Pitha Perumbadu. 
PICTORIAL BLOOD LOSS ASSESSMENT SCORE 
Software: spss17 version  
Variables: PBAC score– before treatment, after treatment  
Number of cases: 30  
S.NO OP.NO 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
PROGNOSIS 
1 4819 335 95 Good 
2 684 295 145 Moderate 
3 8610 276 180 Mild 
4 891 340 80 Good 
5 124 350 100 Good 
6 2768 323 95 Good 
7 8802 355 185 Mild 
8 5812 250 95 Good 
9 3196 405 125 Moderate 
10 1004 402 100 Good 
11 3663 211 98 Good 
12 3797 285 95 Good 
13 8539 265 100 Good 
14 3842 308 85 Good 
15 825 295 135 Moderate 
16 6713 213 90 Good 
17 6942 305 100 Good 
18 2756 284 100 Good 
19 5585 295 90 Good 
20 7293 272 100 Good 
21 5007 225 130 Moderate 
22 728 230 95 Good 
23 4927 360 140 Moderate 
24 6610 200 95 Good 
25 8665 230 100 Good 
26 8404 275 95 Good 
27 5582 320 90 Good 
28 320 420 300 Mild 
29 7497 310 99 Good 
30 1397 355 145 Moderate 
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PBAC SCORE BEFORE TREATMENT 
 
  Frequency percentage 
 
Valid  
        1.00 
        2.00 
        3.00 
16 
11 
3 
53.3 
36.7 
10.0 
 Total 30 100.0 
 
1= 200-300 points 
2= 301-400 points 
3=401-500 points 
  PBAC SCORE BEFORE TREATMENT 
Mean 299.7333 
Std. Deviation 58.64030 
Minimum score 200.00 
Maximum score 420.00 
 
AFTER TREATMENT 
 
PBAC SCORE AFTER TREATMENT 
 
  Frequency percentage 
 
Valid  
        1.00 
        2.00 
        3.00 
21 
6 
3 
70.0 
20.0 
10.0 
 Total 30 100.0 
 
            1= ≤ 100       
2 =101 – 150    
            3 = > 150 
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PBAC SCORE AFTER TREATMENT 
 
Inference:   
By using PCAB, in before treatment the mean score was 299.73. The 
maximum score was 200 and the minimum score was 420.  Whereas in the after 
treatment there was a significant decrease in the scores, the mean score was 116.066, 
the maximum score was 80 and the minimum score was 300.               
 
 
 
 
 
Mean 116.0667 
Minimum 80.00 
Maximum 300.00 
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     GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
AN OPEN NON-RANDOMIZED CLINICAL TRIAL OF 
MAAMPISIN CHOORANAM 
IN PITHA PERUMBADU (MENORRHAGIA) 
INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have 
had the opportunity to ask questions about it and any questions I have asked have 
been answered to my satisfaction. 
            I   consent voluntarily to participate in this study and understand that I have 
the   right to withdraw from the study at any time without in any way it affecting my 
further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.”                                                   
Date: 
 Signature of a witness                                            Left thumb Impression of the 
Participant     
(Selected by the participant bearing no connection with the survey team)       
Station:                                                                                  
Signature of participant:  
Signature of the Guide:    Signature of the Investigator:   
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muR rpj;j kUj;Jtf; fy;Âup;> nrd;id-106 
    mwpQu; mz;zh kUj;Jtkid nrd;id 
     gpj;j ngUk;ghL Neha;f;fhd rpj;j kUe;jpd;  (khk;gprpd; #uzk;) 
     gupfupg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;fhd jfty; gbtk; 
    xg;Gjy; gbtk; 
Ma;thsuhy; rhd;wspf;fg;gl;lJ 
 ehd; ,e;j Ma;it Fwpj;j midj;J tpguq;fisAk; Nehahspf;F GupAk; 
tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd;. 
Njjp:        ifnahg;gk;: 
,lk;:        ngau;: 
    Nehahspapd;  xg;Gjy; 
   vd;dplk; ,e;j Ma;tpd; fhuzj;ijAk;, kUe;jpd; jd;ik kw;Wk; 
kUj;Jt topKiw gw;wpAk; njhlu;e;J vdJ cly; ,af;fj;ij 
fz;fhzpf;fTk,; mjid ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l 
gupNrhjidfs; gw;wp jpUg;jp mspf;Fk; tifapy; Ma;T kUj;Jtuhy; tpsf;fpf; 
$wg;gl;lJ. 
   ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky;> 
vg;nghOJ Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vd;id tpLtpj;Jf; nfhs;Sk; 
cupikia njupe;jpUf;fpd;Nwd;. ehd; vd;Dila Rje;jpukhf Nju;T nra;Ak; 
cupikiaf; nfhz;L Neha;f;fhd khk;gprpd; #uzk; kUe;jpd; gupfupg;Gj; 
jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;F vd;id cl;gLj;j xg;Gjy; 
mspf;fpNwd;. 
Njjp:        ifnahg;gk;: 
,lk;:        ngau;: 
 
Njjp:        rhl;rpf;fhuu; ifnahg;gk;: 
,lk;:        ngau;: 
cwTKiw: 
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CASE SHEET PROFORMA 
 GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL,  
CHENNAI-106  
POST GRADUATE DEPARTMENT BRANCH –I MARUTHUVAM  
CASE SHEET PROFORMA FOR PITHA PERUMBADU 
OP No / IP No :     Nationality :
 Indian              
Ward No  :     Religion :                  
Bed No  :     D.O.A  :                                                                                             
Name   :     D.O.D  :     
Age   :                                                                                                
Sex   :    Female    Diagnosis :        
Occupation  :                                                                                           
Income  :                                                                                                                                                                      
Permanent Address :            
 
Temporary Address :   Govt. Siddha Medical college,    
                                           Chennai-600106  
1.Complaints and duration :    
 
 
 
2. History of present illness :  
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3. History of past illness :             
4. Personal history  :      
5. Occupational history :               
6. Menstrual history  :   
a) Regularity of cycle :   Regular / Irregular    
b) Length of cycle (days) :       
c) Duration of flow (days)    :      
d) Level of flow                     :    Low/ Moderate /Heavy   
e) Abdominal pain  :    Nil/ Mild/ Moderate/ Severe   
f) LMP                                   :   
g) Number of pads used     
         per cycle   : 
7. Personal Habits  :   Veg /non-veg / smoker /Alcoholic / Tobacco hewer    
8. Family History  :       
                                                                                                                                                                      
9.Obstetric History               :    
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GENERAL EXAMINATION  
Patient consciousness :   
Body Built   : 
Nourishment   : 
Anaemia   : 
Jaundice   : 
Cyanosis   : 
Clubbing   : 
JVP    :  
Tracheal deviation  : 
Pedal oedema  : 
Lymph adenopathy  :  
 
VITAL SIGNS 
Heart rate   : 
Pulse rate   : 
Respiratory rate  : 
Blood Pressure  : 
Body Temperature  : 
Weight   : 
Height    : 
   
SIDDHA ASPECT 
 
NILAM 
Kurinchi   : 
Mullai    : 
Marutham   : 
Neithal   : 
Palai    : 
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PARUVAKAALAM  
Kaar kalam  : 
Koor kalam  : 
Munpani kalam : 
Pinpani kalam : 
Elavenil kalam : 
Muduvenil  :   
YAAKKAI (Udal)  
Vaatham  : 
 Pitham  :             
Kabam  :   
Kalappu  : 
GUNAM  
Satthuvam  :  
Rajotham  :  
Thamasam  :   
PORI/PULANGAL (SENSORY ORGANS)  
Mei (Sensation) : 
Vaai ( Taste)     :  
Kan( Vision)       : 
Mooku ( Smell)     :  
Sevi ( Hearing)    :   
KANMENTHRIYAM/KANNMAVIDAYAM [MOTOR ORGANS]  
Kai ( Dhaanam)     :   
Kaal ( Kamanam)     :  
Vaai ( Vasanam)     :   
Eruvaai( Visarkkam)   :   
Karuvaai (Aanantham)  :     
                                                                                  CASE SHEET PROFORMA 
 
An open non-randomized clinical trial of Maampisin Chooranam in Pitha Perumbadu  Page 151 
 
UYIR THATHUKKAL 
VATHAM   
Praanan     :   
Abanan     :   
Viyanan     :   
Udanan     :   
Samanan     :   
Nagan      :   
Koorman     :   
Kirukaran     :  
Devathathan   :  
Thananjeyan  :  
PITHAM  
Anar pitham    :  
Ranjaga pitham   :  
Saathaga pitham   :  
Pirasaga pitham   :  
Alosaga pitham   :     
KAPAM 
  Avalambagam   :   
Kilethagam     :   
Pothagam     :  
Tharpagam     :  
Santhigam     :   
 
UDALTHAATHUKKAL  
Saaram     :   
Senner     :   
Oon       :  
Kozhuppu     :  
Enbu       :  
Moolai     : 
Suronitham     : 
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ENVAGAI THERVUGAL  
1. Naa      : 
  2. Niram     :  
3. Mozhi     :  
4. Vizhi     :   
5. Sparisam     :  
6. Malam     :  
7. Naadi     :  
8. Moothiram  :   
a) Neer Kuri  :                          
Niram    :    
Manam   :    
Edai     :    
Nurai    :     
Enjal    :   
b) Nei Kuri   :   
MODERN ASPECT  
Sytemic Examination 
Inspection       :   
Palpation       :   
Percussion       :   
Auscultation      :   
Others Systems  
Cardio Vascular System    :  
Respiratory system    :  
Central nervous system   :  
Genito urinary system   :  
Endocrine system      :  
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CLINICAL SIGNS AND SYMPTOMS OF PERUMBADU  
 
 
Symptoms 
 
 
Before 
Treatment 
 
                              After Treatment                
I 
7 days 
II 
9 Days 
III 
12 
Days 
IV 
30 
Days 
V 
48 
Days 
 
1.Vaginal Bleeding               
 No of pads                            
 
      
 
2. Vaginal Bleeding  
No of days   
 
      
 
3.Passing blood 
clots        
 
      
 
4. Abdomen pain   
 
      
 
5. Loss of appetite        
 
      
 
6. Anaemia        
 
      
 
7.Myalgia        
      
 
8.Tiredness        
 
      
  
9. Head ache        
 
      
 
10. Giddiness         
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INVESTIGATIONS 
1. BLOOD INVESTIGATIONS :   
    
 
 
2. URINE INVESTIGATION 
 
BLOOD INVESTIGATIONS    
 
BEFORE 
TREATMENT     
 
AFTER 
TREATMENT   
 
Hb (gms/dl)    
T.RBC(millions cells/cu.mm)    
 
ESR (mm) 
½ hr      
1 hr   
T.WBC (cells/cu.mm)       
 
   
      Differntial  
       Count (%) 
Polymorphs   
Lymphocytes   
Eosinophils   
BLOOD 
INVESTIGATIONS   
 
 
    BEFORE TREATMENT  
 
     AFTER TREATMENT   
 
Bleeding Time   
Clotting Time   
Blood glucose (mg/dl) (R)      
Blood Urea   
Serum Cholestrol   
URINE 
INVESTIGATIONS 
 
 
BEFORE TREATMENT     
 
AFTER TREATMENT   
 
Albumin   
Sugar   
Deposits   
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3. SONOGRAPHY          
  USG Abdomen and Pelvis   
  4. SMEAR STUDY       
PAP smear       
 
 CASE SUMMARY     
 DIAGNOSIS                       :      PITHA PERUMBADU   
 TRIAL DRUG                      :     Maampisin Chooranam 
 Dose                                   :     2  gm; Thrice a day after food .   
 Duration of Treatment      :     1-15 days for 3 consecutive cycles 
 
REPORTS :   
 
DATE 
 
 
WEEKLY REPORTS 
 
MEDICINE 
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DATE 
 
 
WEEKLY REPORTS 
 
 
 
MEDICINE 
 
 
 
  
 
ADVICE : 
 DO’S : 
 Take balanced and healthy food.  
 Take rest in comfort bed    
Use sanitary pads.  
 DON’TS    : 
 Don’t travel  
 Don’t do heavy work   
PROGNOSIS AT THE END OF THE TREATMENT : 
 Reducing in clinical symptoms and by comparing the following parameters before 
and after treatment  
1. Quantity of Menstrual blood flow based on PBAC score  
2. Number of pads used for a cycle 
3..Haemoglobin level.     
 
Medical Officer Signature:                                                                      HOD 
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